WO1999060025A1 - Anticorps recombines de gene - Google Patents
Anticorps recombines de gene Download PDFInfo
- Publication number
- WO1999060025A1 WO1999060025A1 PCT/JP1999/002661 JP9902661W WO9960025A1 WO 1999060025 A1 WO1999060025 A1 WO 1999060025A1 JP 9902661 W JP9902661 W JP 9902661W WO 9960025 A1 WO9960025 A1 WO 9960025A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- chain
- amino acid
- region
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Definitions
- the present invention is useful for the diagnosis or treatment of diseases in which the disease state progresses due to abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, retinopathy of diabetes mellitus, retinopathy of prematurity and dryness.
- abnormal angiogenesis such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, retinopathy of diabetes mellitus, retinopathy of prematurity and dryness.
- the present invention relates to a method for diagnosing solid tumors, rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity and xerosemia using antibodies, diagnostic agents and therapeutic agents.
- Angiogenesis plays an important role in the development and tissue organization of vertebrate individuals, and also plays a role in the luteal formation, transient proliferation of the endometrium and placental formation in the sexual cycle of mature individuals (females). Is also closely involved. In addition, angiogenesis is involved in the pathogenesis or promotion of solid tumor growth or metastasis, diabetic retinopathy and rheumatoid arthritis [J. Biol. Ch, 267, 10931]. (1992)].
- Angiogenesis is triggered by the secretion of angiogenic factors, which destroys the basement membrane and stroma by the secretion of proteases from endothelial cells of existing blood vessels in the vicinity of the secreted angiogenic factors, followed by migration of the endothelial cells [J. Biol. Chem., 267, 10931 (1992)]
- the factors that induce lk vascularization include vascular endothelial cells
- VPF vascular endothelial growth factor
- VEGF vascular endothelial growth factor
- VPF / VEGF vascular endothelial growth factor
- the activity of VEGF has been reported so far on proliferation of vascular endothelial cells [Biochem. Biophys. Res. Comm., 161, 851 (1989)], migration promotion activity [J. Immunology, 152, 4149 (1994)] ], Meta-oral protease secretion promoting activity [J. Cell.
- VEGF is a growth factor with extremely high specificity for vascular endothelial cells [Biochem. Biophys. Res. Comm., 161, 851 (1989)], and has a different molecular weight due to alternative splicing of mRNA 4 type has been reported that the protein is present [J. Biol. Chem., 67 , 26031 (1991)] 0
- VEGF vascular endothelial growth factor
- an anti-VEGF monoclonal antibody exhibits a tumor growth inhibitory effect [Nature, 362, 841 (1993)]. Further, it has been reported that an anti-VEGF monoclonal antibody can suppress cancer metastasis in a metastatic cancer model of a human tumor in nude mice [Cancer Research, 56, 921 (1996):]. High concentrations of VEGF are detected in human pleural effusions and ascites in humans, suggesting that it may be a major factor in pleural effusion and ascites retention. [Biochimica et Biophysica Acta, 1221, 211 (1994)].
- angiogenesis In diabetic retinopathy, abnormal angiogenesis causes retinal detachment and vitreous hemorrhage leading to blindness, but it has been reported that angiogenesis in diabetic retinopathy and VEGF levels in the patient's eye are positively correlated [ New England J. Medicine, 331, 1480 (1994)]. In addition, it has been reported that angiogenesis is suppressed when VEGF activity is suppressed by intraocular administration of an anti-VEGF neutralizing monoclonal antibody in a monkey retinopathy model [Arch
- Fit-1 ftns-like tyrosine kinase belonging to the receptor tyrosine kinase family [Oncogene, 5, 519 (1990); Science, 255, 989 (1992)] and kinase insert domain-containing receptor (KDR) [W092 / 14748; Proc. Natl. Acad. Science USA, 88, 9026 (1991); Biochem. Biophys. Res. Comm., 187, 1579 (1992) ); W094 / 11499] has been reported.
- Fit-1 and KDR are membrane proteins with a molecular weight of 180-200 kilodaltons, having an extracellular region consisting of seven immunoglobulin-like sites and an intracellular region consisting of tyrosine kinase sites. It has been reported that VEGF specifically binds to Fit-1 and KDR at Kd values of 20 pM and 75 pM, and that Flt-1 and KDR are specifically expressed in vascular endothelial cells [ Proc. Natl. Acad. Sci. USA, 90, 7533 (1993); Proc. Natl. Acad. Sci. USA, 90, 8915 (1993)].
- Flt-1 Flt-1 in various diseases has been described in tumor vascular endothelial cells of human glioplastoma tissue [Nature, 359, 845 (1992)] and tumor vascular endothelial cells of human gastrointestinal cancer tissue [Cancer Research, 53, 4727 (1993)], it is reported that the expression of flt-1 mRNA is higher than that of vascular endothelial cells in normal tissues. Furthermore, it has been reported that the expression of flt-1 mRNA is also observed in vascular endothelial cells of the joints of patients with rheumatoid arthritis by in situ hybridization (in situ hybridization) [J.
- Fit-1 has been reported to bind VEGF and autophosphorylate the intracellular domain [Science, 255, 989 (1992)], but its detailed function is unknown.
- flt-1 knockout mice in which the flt-1 gene has been disrupted have an abnormal vascular structure due to abnormal vascular endothelial cell morphology in the early formation of blood islands and subsequent angiogenesis, resulting in embryonic 8.5-9.5 day old
- Fit-1 plays an essential function in vascular endothelial cell tube formation during angiogenesis [Nature, 376, 66 (1995)].
- antibodies that bind to the VEGF receptor Fit-1 and have neutralizing activity against Flt-1 include solid tumor growth or metastasis, arthritis in rheumatoid arthritis, diabetic retinopathy, and retinopathy of prematurity. It is expected to be useful for diagnosis and treatment of diseases in which the disease state progresses due to abnormal angiogenesis such as desiccation.
- a monoclonal antibody derived from a non-human animal can be converted to a human chimeric antibody or a human CDR (complementary
- Human chimeric antibodies are antibodies in which the antibody variable region (hereinafter, referred to as V region) is derived from a non-human animal antibody and the antibody constant region (hereinafter, referred to as C region) is derived from a human antibody [Proc. Natl. Acad. Sci. USA, 81, 6851 (1984)], when administered to humans, it was reported that antibodies to monoclonal antibodies derived from non-human animals were hardly elicited, and the half-life in blood was increased by 6 times. Natl. Acad. Sci. USA, 86, 4220 (1989)].
- V region antibody variable region
- C region antibody constant region
- the human-type CDR-grafted antibody converts human antibody CDRs to antibodies derived from non-human animals. [Nature, 32 ⁇ , 522 (1986)], which has reduced immunogenicity and increased blood half-life by 4 to 5 times compared to mouse antibodies in monkey experiments. Have been reported [J. Immunol., 147, 1352 (1991)].
- chimeric antibodies and humanized antibodies that specifically bind to the human VEGF receptor Fit-1 have side effects due to the absence of antibodies to monoclonal antibodies derived from non-human animals when administered to humans.
- Diseases that progress due to abnormal angiogenesis such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, and dryness due to a decrease and prolonged blood half-life High therapeutic effects are expected.
- single-chain antibodies and disulfide-stabilized antibodies that specifically bind to the human VEGF receptor Fit-1 can be used for the growth or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, and retinopathy of prematurity. It is expected to have a high diagnostic and therapeutic effect on diseases in which the disease state progresses due to abnormal angiogenesis such as freshness.
- the anti-human VEGF receptor Fit-1 antibody can detect and suppress angiogenesis sites, and is expected to be useful for diagnosis and treatment of diseases in which the disease progresses due to abnormal angiogenesis as described above.
- the present invention relates to the following (1) to (68).
- the recombinant antibody of the present invention is obtained by genetically modifying the monoclonal antibody of the present invention. It has been modified using technology.
- Recombinant antibodies include humanized antibodies and antibodies produced by genetic recombination, such as antibody fragments such as single chain antibodies and disulfide stabilized antibodies.
- those that have the characteristics of a monoclonal antibody, have low antigenicity, and have an extended half-life in blood are preferred as therapeutic agents.
- the humanized antibody in the present invention includes a human chimeric antibody and a human CDR-grafted antibody.
- the antibody fragment of the present invention is an antibody fragment that specifically reacts with the human VEGF receptor Fit-1, Fragment of antigen binding (abbreviated as Fab), Fab, F (ab,) 2 , single-chain antibody ( single chain Fv; hereinafter abbreviated as scFv) and disulfide stabilized Fv (hereinafter abbreviated as dsFv).
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- Fab fragment of antigen binding
- the human chimeric antibody is composed of an antibody non-human animal heavy chain variable region (hereinafter, the heavy chain is referred to as H chain, the variable region is referred to as HV or VH as V region) and a light chain variable region (hereinafter, light chain is referred to as L
- H chain an antibody non-human animal heavy chain variable region
- HV or VH variable region
- L light chain variable region
- An antibody consisting of a constant chain hereinafter also referred to as CH as a C region
- a light chain constant region of a human antibody hereinafter also referred to as CL).
- the human chimeric antibody of the present invention obtains cDNAs encoding VH and VL from a hybridoma that produces a monoclonal antibody that specifically reacts with human VEGF receptor Flt-1, and obtains human antibody CH and human antibody
- a human-type chimeric antibody expression vector can be constructed by inserting each into an expression vector for animal cells having a gene encoding CL, and can be expressed and produced by introducing the vector into animal cells.
- any of the I Takeno globulin (hereinafter abbreviated as ig) by even those belonging to the class les, but, IgG type, more belong to IgG-type IgGl, IgG2, I g
- the C region of immunoglobulin such as G3 and IgG4 is preferred.
- the human CDR-grafted antibody means an antibody in which the CDRs of VH and VL of a human antibody have been substituted with the CDR sequences of antibodies of a non-human animal, respectively.
- the human-type CDR-grafted antibody of the present invention comprises a VH and VL CDR sequence of any human antibody, which is a VH and VL CDR sequence of an antibody of a non-human animal, which specifically reacts with human VEGF receptor Flt_l.
- CDNAs encoding the respective substituted V regions were constructed, and inserted into animal cell expression vectors having genes encoding human antibody CH and human antibody CL, respectively, to construct human CDR-grafted antibody expression vectors. It can be produced by introducing it into animal cells and expressing it.
- the structure of the human CDR-grafted antibody C region of the present invention may be any one of the immunoglobulin (lg) classes, such as IgG, IgGl, lgG2, IgG3, IgG4, etc.
- the C region of the globulin is preferred.
- the antibody VH CDR1S of the humanized antibody comprising the amino acid sequence of SEQ ID NOS: 5, 6 and 7, or the amino acid sequence of SEQ ID NOS: 11, 12 and 13.
- Human chimera antibody power The human chimera according to (8) above, comprising VH and VL of monoclonal antibodies specifically reacting with the human VEGF receptor Fit-1, and CH and CL of human antibodies. antibody.
- VH and V amino acid sequence is a monoclonal antibody selected from monoclonal antibody KM1732 (FERM BP-5698) or monoclonal antibody KM1750 (FERM BP-5700)
- the human chimeric antibody according to the above (11) which has the same amino acid sequence as that of VH and V.
- the human chimeric antibody according to (11) above, wherein the human chimeric antibody specifically reacting with human VEGF receptor Fit-1 is selected from KM2532 and KM2550.
- the human VL CDR of the human CDR-grafted antibody which has the amino acid sequence of SEQ ID NOs: 8, 9 and 10 or the amino acid sequence of SEQ ID NOs: 14, 15 and 16; G type CDR-grafted antibody.
- the transformant described in (32) is cultured in a medium, and the human CDR-grafted antibody described in (22) to (29) is produced and accumulated in the culture, and the antibody is isolated from the culture.
- a method for producing an antibody which comprises collecting the antibody.
- the antibody according to the above (6) wherein the antibody fragment is any one selected from the group consisting of Fab, Fab ', F (ab') 2 , a single-chain antibody and a disulfide-stabilized Fv.
- Fab is obtained by degrading the peptide part above two disulfide bonds that bridges two H chains in the hinge region of IgG with the enzyme papain. This fragment is composed of the body and has an antigen-binding activity with a molecular weight of about 50,000.
- the Fab of the present invention can be obtained by treating an antibody specifically reacting with the human VEGF receptor Fit-1 with papain.
- Fab encoding can be produced by inserting a DNA encoding the Fab fragment of the antibody into an expression vector for animal cells and introducing the vector into animal cells for expression.
- Fab is a fragment having a molecular weight of about 50,000 and having an antigen-binding activity in which the disulfide bond between the hinges of F (ab,) 2 is cleaved.
- the Fab of the present invention can be obtained by treating an antibody that specifically reacts with the human VEGP receptor Fit-1 with a reducing agent dithiothreitol.
- Fabs can be produced by inserting a DNA encoding the Fab or fragment of the antibody into an expression vector for animal cells and introducing the vector into animal cells for expression.
- F (ab ') 2 is obtained by degrading the lower part of two disulphide bonds in the hinge region of IgG with the enzyme trypsin. Which is a fragment having an antigen-binding activity.
- the F (ab,) 2 of the present invention can be obtained by trypsinizing an antibody that specifically reacts with the human VEGF receptor Fit-1.
- DNA encoding the F (ab,) 2 fragment of the antibody is inserted into an expression vector for animal cells, and the vector is expressed by introducing the vector into animal cells to produce F (ab ') 2.
- a single-chain antibody (hereinafter, also referred to as scFv) is obtained by linking one VH and one VL with an appropriate peptide linker (hereinafter, referred to as P), and is composed of VH—P—VL or VL—P — Indicates VH polypeptide.
- VH and VL contained in the scFv used in the present invention either the monoclonal antibody of the present invention or the human CDR-grafted antibody can be used.
- cDNAs encoding VH and VL were obtained from a hybridoma producing an antibody that specifically reacts with human VEGF receptor Fit-1, and a single-chain antibody expression vector was constructed. Thereafter, the cDNA can be introduced into the expression vector and expressed by introducing the expression vector into Escherichia coli, yeast, or animal cells to produce the cDNA.
- a disulfide-stabilized antibody (hereinafter, also referred to as dsFv) refers to a polypeptide in which one amino acid residue in each of VH and VL has been substituted with a cysteine residue via a disulfide bond.
- the amino acid residue to be substituted for the cysteine residue was determined by the method described by Reiter et al. According to [Protein Engineering, 7, 697 (1994)], selection can be made based on prediction of the three-dimensional structure of the antibody.
- the VH or VL contained in the disulfide stabilized antibody of the present invention either a monoclonal antibody or a human CDR-grafted antibody can be used.
- the disulfide-stabilized antibody of the present invention obtains cDNAs encoding VH and VL from a hybridoma producing an antibody that specifically reacts with human VEGF receptor Fit-1, and inserts the cDNAs into an appropriate expression vector. Alternatively, it can be produced by introducing the expression vector into Escherichia coli, yeast, or animal cells for expression.
- the amino acid sequence of the CDRs of VH and VL of the main chain antibody has the same amino acid sequence as that of the CDRs of VH and VL of the monoclonal antibody that specifically reacts with human VEGF receptor Fit-1;
- the amino acid sequence of the CDR of VH or VL of the main chain antibody contains the amino acid sequence of SEQ ID NO: 5, 6, or 7 as the CDR of VH, and the amino acid sequence of SEQ ID NO: 8, 9, or 10 (37) above.
- VH and VL CDR amino acid sequence power of a single-chain antibody The amino acid sequence of SEQ ID NO: 11, 12 and 13 is included as a VH CDR, and the amino acid sequence of SEQ ID NO: 14, 15 and 16 is VL
- amino acid sequence of VH of the chain antibody comprises the amino acid sequence of SEQ ID NO: 91 or SEQ ID NO: 95
- amino acid sequence of VL comprises the amino acid sequence of SEQ ID NO: 93, SEQ ID NO: 94 or SEQ ID NO: 96
- the amino acid sequence of VH and VL of the disulfide-stabilized antibody has the same amino acid sequence as the amino acid sequence of VH and VL of the monoclonal antibody that specifically reacts with the human VEGF receptor Fit-1 (44). )).
- the amino acid sequence of the VH and VL CDRs of the disulfide-stabilized antibody has the same amino acid sequence as the VH and VL CDRs of the monoclonal antibody that specifically reacts with human VEGF receptor Fit-1. And the disulfide-stabilized antibody according to (44).
- the amino acid sequence of CDRs of VH and VL of a disulfide-stabilized antibody contains the amino acid sequence of SEQ ID NOS: 5, 6, and 7 as a CDR of VH, and the amino acid sequence of SEQ ID NOs: 8, 9, and 10 is VL.
- the amino acid sequence of the CDRs of VH and VL of the disulfide-stabilized antibody comprises the amino acid sequence of SEQ ID NO: 11, 12, and 13 as the CDR of VH, and the amino acid sequence of SEQ ID NO: 14, 15, and 16 to VL
- the amino acid sequence of VH of the disulfide-stabilized antibody includes the amino acid sequence of SEQ ID NO: 91 or SEQ ID NO: 95, and the amino acid sequence of VL includes the amino acid sequence of SEQ ID NO: 93, SEQ ID NO: 94, or SEQ ID NO: 96,
- a peptide comprising an amino acid sequence selected from CDRs of the H chain V region and L chain V region of a recombinant antibody specifically reacting with the human VEGF receptor Fit-1 described in (1) above; .
- a fusion antibody in which the antibody or peptide described in any of (1) to (55) above is chemically or genetically engineered with a radioisotope, protein, or low-molecular-weight drug; or An antibody or peptide that is a fusion peptide.
- a fusion antibody or fusion peptide refers to an antibody or peptide obtained by chemically or genetically binding a radioisotope, a protein, a low-molecular-weight drug, or the like to the above-described antibody or peptide.
- the fusion antibody or fusion peptide of the present invention can be produced by chemically binding an antibody or peptide that specifically reacts with human VEGF receptor Flt-1 with a radioisotope, protein, or low-molecular-weight drug. it can.
- a cDNA encoding the protein is ligated to a cDNA encoding the antibody or peptide, inserted into an appropriate expression vector, and the expression vector is transformed into E. coli, yeast, or animal. It can be produced by expressing it in cells.
- Low molecular drugs include alkylating agents such as nitrogen mustard and cyclophosphamide, antimetabolites such as 5-fluorouracil and methotrexate, antibiotics such as mitomycin C and daunorubicin, and plant alkaloids such as vincristine and vinblastine.
- Ta Anticancer drugs such as hormones such as moxifuyun and dexamethasone [clinical oncology (Japan Clinical Tumor Study Group, 1996, Cancer and Chemotherapy)], or nonsteroidal drugs such as noid oral cortisone and prednisone, aspirin and indomethacin.
- Immunomodulators such as steroids, gold thiomalate, and penicillamine; immunosuppressants such as cyclophosphamide and azathioprine; anti-inflammatory drugs such as antihistamines such as chlorpheniramine maleate and clemacitin [Inflammation and anti-inflammatory therapy Showa 57 Year Medical and Dental Publishing Co., Ltd.].
- a human VEGF receptor Flt-1 A method for immunologically quantifying cells that have expressed on the cell surface.
- An angiogenesis abnormality comprising, as an active ingredient, the antibody or peptide described in any one of (1) to (17), (22) to (29), and (34) to (56). Diagnostic agent for diseases whose disease state progresses due to
- Solid tumors include breast cancer, prostate cancer, colon cancer, stomach cancer, lung cancer and the like.
- Angiogenesis comprising, as an active ingredient, the antibody or peptide described in any one of (1) to (17), (22) to (29), and (34) to (56).
- the following shows the anti-human VEGF receptor Fit-1 humanized antibody and the anti-human VEGF receptor Fit-1 antibody fragment that specifically react with human VEGF receptor Fit-1 or have neutralizing activity against human Fit-1
- the following describes the method for producing E. coli, and the method for detecting and quantifying the human VEGF receptor Fit-1 using the antibody.
- Antigens required to produce anti-human VEGF receptor Fit-1 monoclonal antibody include cells that express human VEGF receptor Fit-1 on the cell surface or cell membrane fraction thereof, or cells of different lengths. Examples include a soluble human VEGF receptor Fit-1 protein having an outer region, or a fusion protein of the protein with the Fc portion of an antibody.
- Cells expressing the human VEGF receptor Flt-1 on the cell surface include NIH3T3-Fit-1 cells [Oncogene, 10, 135 (1995)] and the like.
- DNA encoding the human VEGF receptor Fit-1 was obtained using a genetic engineering technique, and a soluble human VEGF receptor Flt-1 protein having an extracellular region having different amino acid lengths or the protein was obtained. It can also be expressed as a fusion protein of the antibody and the Fc portion of the antibody to serve as an antigen.
- the host may be any host, such as bacteria, yeast, animal cells, and insect cells, as long as it can express the gene of interest.
- bacteria include bacteria of the genus Escherichia, such as Escherichia coli and Bacillus subtilis, and those of the genus Bacillus.
- yeast include Saccharomyces' cerevisiae (Shiapcharyces cerevisiae) and Shizo Saccharomyces bomb (Scj2 zosa_ ⁇ haroipyces pombe).
- animal cells include Namalva cells, which are human cells, COS cells, which are monkey cells, and CHO cells, which are Chinese hamster cells.
- insect cells include Sf9, Sf21 (Pharmingen), High Five (Invitrogen) and the like.
- any vector can be used as long as the DNA can be incorporated and can be expressed in a host cell.
- the expression vector When a bacterium, for example, Escherichia coli (Escherichia £ 2) is used as a host, the expression vector includes a promoter, a ribosome binding sequence, the DNA of the present invention, a transcription termination sequence, and in some cases, a promoter control sequence.
- a promoter for example, commercially available pGEX (Pharmacia), pET system (Novagen) and the like are exemplified.
- pGEX Pharmacia
- pET system Novagen
- protoplast Any method such as the method (JP-A-63-248394) can be used.
- yeast When yeast is used as a host, for example, YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419) and the like are used as expression vectors.
- a method for introducing a recombinant vector into yeast includes, for example, the elect-portion method [Methods. Enzymol., 194. 182 (1990)], the Sufero plast method [Proc. Natl. Acad. Sci. USA, 84, 1929 (1978)] and the lithium acetate method [J. Bacteriol., 153, 163 (1983)].
- promoters of the IE (immediate early) gene of cytomegalovirus (CMV), SV40, and metamouth thionein can be used. Promoters and the like. Further, the enhancer of the IE gene of human CMV may be used together with the promoter.
- a method for introducing DNA into animal cells includes, for example, the elect-portion method [Cytotechnology, 3, 133 (1990)] and the calcium phosphate method (Japanese Unexamined Patent Application Publication No. 2-227075), and the Lipofxion method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)].
- an insect cell When an insect cell is used as a host, for example, it is described in Current 'Protocols (Supplement 1-34), Baculovirus' Expression' Vectors, A 'Laboratory' manual (Baculovirus expression vectors, A laboratory manual), etc.
- the protein can be expressed by the applied force method. That is, the recombinant gene transfer vector and baculovirus described below are co-transfected into insect cells to obtain a recombinant virus in the insect cell culture supernatant, and then the recombinant virus is infected into the insect cells. Obtain protein-expressing insect cells.
- PVL1392 As the gene transfer vector, for example, PVL1392, pVL1393, pBlueBacIII (all manufactured by Invitrogen) and the like are used.
- baculovirus for example, Autographa californica nuclear polyhedrosis virus, which is a virus that infects night insects belonging to the moth family, is used.
- Examples of a method for co-transferring the above-described recombinant gene transfer vector and the above baculovirus into insect cells to prepare a recombinant virus include a calcium phosphate method (Japanese Patent Laid-Open No. 2-227075), a lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)].
- insect cells such as Sf9, Sf21 or High Five described above were produced.
- a protein can also be produced by infecting the recombinant virus with the recombinant virus [Bio / Technology, 6, 47 (1988)].
- Molecular 'cloning 2nd edition As a method for expressing a gene, in addition to direct expression, secretory production, fusion protein expression and the like have been developed, and any method can be used. For example, described in Molecular Cloning 2nd edition, Cold Spring Harbor Lab. Press, New York (1989) (hereinafter abbreviated as Molecular 'cloning 2nd edition). It can be performed according to the method.
- the proteins to be fused include ⁇ -galactosidase, protein ⁇ , IgG binding region of protein ⁇ , chloramphenicol 'acetyltransferase, poly (Arg), poly (Glu), protein G, maltose binding protein, daltathione S-transferase. , Polyhistidine chain (His-tag), S-peptide, DNA-binding protein domain, Tac antigen, thioredoxin, green 'fluorescent' protein, and any antibody epitope [Experimental Medicine, 13, 469-474 ( 1995)].
- the transformant obtained as described above is cultured in a medium, the full-length or partial fragment of the human VEGF receptor Flt-1 is produced or accumulated as it is or as a fusion protein in the culture, and collected from the culture.
- the full length or partial fragment of human VEGF receptor Fit-1 can be produced as it is or as a fusion protein.
- the method for culturing the transformant of the present invention in a medium is performed according to a usual method used for culturing a host.
- the medium for culturing the transformant obtained by using a microorganism such as Escherichia coli or yeast as a host contains a carbon source, a nitrogen source, inorganic salts, and the like, which can be used by the microorganism, so that the cultivation of the transformant is efficient.
- a carbon source such as Escherichia coli or yeast
- Cultivation is usually performed at 15 to 40 ° C for 16 to 96 hours under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the pH is maintained at 3.0 to 9.0.
- the pH is adjusted using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium as needed.
- a medium for culturing transformants obtained using animal cells as a host generally used media are used. RPMI1640 medium, Eagle's MEM medium, or a medium obtained by adding fetal calf serum or the like to these mediums is used. Cultures, 5% C0 2 presence usually performed 3-7 days at 35 to 37 ° C, the culture if necessary, kanamycin, may be added to the antibiotic penicillin such as the medium.
- TNM-FH medium As a culture medium for culturing the transformant obtained using insect cells as a host, commonly used TNM-FH medium [Pharmingen], Sf900IISFM [Life Technologies (Siba e Technologies)] ExCell400, ExCell405 [all manufactured by JRH Biosciences] and the like.
- the culture is performed at 25 to 30 ° C for 1 to 4 days, and an antibiotic such as gentamicin may be added to the medium during the culture, if necessary.
- the power of serum contained in the culture medium of animal cells and insect cells In order to facilitate purification of the full-length or partial fragment of human VEGF receptor Flt-1 as it is or as a fusion protein, preferably a serum-free medium Is used.
- the full-length or partial fragment of the human VEGF receptor Fit-1 is accumulated in host cells either as it is or as a fusion protein, after culturing, the cells are centrifuged, suspended in an aqueous buffer, and then suspended. The cells are disrupted by a sonication method, a French press method, or the like, and the protein is recovered by centrifugation and purification. .
- the insoluble substance is solubilized with a protein denaturing agent, and then diluted to a solution that does not contain the protein denaturing agent or is diluted so that the concentration of the protein denaturing agent does not change the protein. Or by dialysis to form the three-dimensional structure of the protein.
- the expressed protein can be recovered in the culture supernatant. Isolation and purification include solvent extraction, fractional precipitation with organic solvents, salting out, dialysis, centrifugation, ultrafiltration, ion exchange chromatography, gel filtration chromatography, hydrophobic chromatography, affinity chromatography, and reverse chromatography. Separation operations such as phase chromatography, crystallization, and electrophoresis can be performed alone or in combination.
- the animal used for immunization may be any animal, such as a mouse, a rat, a hamster, or a rabbit, as long as it can produce a hybridoma.
- an example using a mouse and a rat will be described.
- a mouse or rat aged 3 to 20 weeks is immunized with the protein obtained in the above 1 (1) as an antigen, and antibody-producing cells are collected from the spleen, lymph nodes, and peripheral blood of the animal. Immunization is performed by subcutaneously, intravenously or intraperitoneally administering the antigen several times with an appropriate adjuvant.
- Adjuvants include Complete Freund's Adjuvant or aluminum hydroxide gel and B. pertussis vaccine.
- N1H3T3 cells expressing the soluble human VEGF receptor Fit-1 or human VEGF receptor Flt_l used as an antigen on the cell surface from the venous plexus or tail vein of the immunized animal 3 to 7 days after each administration The reactivity of the mouse or rat whose serum showed a sufficient antibody titer was confirmed by enzyme immunoassay or the like [Enzyme-linked immunosorbent assay (ELISA): published by Medical Shoin (1976)]. It is a source of producer cells.
- Myeloma cells include 8-azaguanine-resistant mouse (derived from BA and B / c) myeloma cell line P3-X63Ag8-Ul (P3-Ul), a cell line obtained from mice. Immunol., 6, 511 (1976)], SP2 / 0-Agl4 (SP-2) [Nature, 276, 269 (1978)], P3—X63—Ag8653 (653) [J. Immunol., 12 ⁇ 1548 ( 1979)], P3-X63_Ag8 (X63) [Nature, 256, 495 (1975);], and any other myeloma cells that can grow in vitro. Culture and passage of these cell lines are performed according to a known method (Antibody's 'Laboratory' manual), and a cell number of 2 ⁇ 10 7 or more is secured by the time of cell fusion.
- a cell-aggregating medium such as polyethylene glycol-1000 (PEG-1000) is added to fuse the cells, and the cells are suspended in the medium. Cloudy.
- PEG-1000 polyethylene glycol-1000
- MEM medium or PBS 1.83 g of disodium phosphate, 0.21 g of monopotassium phosphate, 7.65 g of salt, 1 liter of distilled water, pH 7.2
- a HAT medium normal medium [glutamine (1.5 mM), 2_mercaptoethanol (5 X 1 (gamma 5 Micromax), gentamicin (10 mu g / ml) and fetal calf serum (FCS) (CSL Ltd., 10%) was added medium] hypoxanthine (10- 4 M), thymidine (1.5 X 10- 5 M) and aminopterin (4 X 10- 7 M) and using a medium ⁇ plus.
- a part of the culture supernatant is taken, and a sample that reacts with the antigen protein and does not react with the non-antigen protein is selected by enzyme immunoassay. Subsequently, cloning is performed by the limiting dilution method, and those having a stable and high antibody titer determined by enzyme immunoassay are selected as monoclonal antibody-producing hybridoma strains.
- the antigen protein or cells expressing the antigen protein are coated on a 96-well plate, and the hybridoma culture supernatant or the purified antibody obtained by the above method is reacted as the primary antibody.
- the plate After the first antibody reaction, the plate is washed and the second antibody is added.
- the second antibody is an antibody obtained by labeling an antibody capable of recognizing the immunoglobulin of the first antibody with biotin, an enzyme, a chemiluminescent substance, a radiation compound, or the like. Specifically, if a mouse is used for preparing the hybridoma, an antibody capable of recognizing mouse immunoglobulin is used as the second antibody.
- hybridoma strain examples include the hybridoma strains KM1732 (FERM BP-5699), KM 1748 (FERM BP-5699) and KM1750 (FERM BP-5700).
- an enzyme, a chemiluminescent substance or a radioactive compound after mixing and reacting the above-mentioned first antibody with human VEGF labeled with biotin, an enzyme, a chemiluminescent substance or a radioactive compound, a reaction according to the labeling substance is performed, whereby human VEGF is The activity of inhibiting the binding to human VEGF receptor Fit-1 can be measured.
- a hybridoma having high human VEGF inhibitory activity can be screened.
- Pristane-treated (2,6,10,14-tetramethylpentadecan (? 1 ⁇ 1 & 06) 0.51 ⁇ was intraperitoneally administered and bred for 2 weeks), 8-10 week-old mice or nude mice were treated with 1 (4 ).
- the anti-human VEGF receptor Fit-1 monoclonal antibody-producing hybridoma cells obtained in 2) above are injected intraperitoneally at 2 ⁇ 10 7 to 5 ⁇ 10 6 cells / animal. In 10 to 21 days, the hybridoma becomes ascites cancer.
- IgG or Ig fraction is collected using a column of Fine GSL2000 (manufactured by Seikagaku Corporation) and used as a purified monoclonal antibody.
- the subclass of the purified monoclonal antibody can be determined using a mouse monoclonal antibody typing kit, a rat monoclonal antibody typing kit, or the like.
- the protein mass can be calculated by the Lowry method or from the absorbance at 280 nm.
- the antibody subclass is an isotype within the class, and includes IgGl, IgG2a, lgG2b, and IgG3 in mouse and IgGl, lgG2, IgG3, and IgG4 in human.
- Mouse IgGl, IgG2a and human IgGl types have complement-dependent cytotoxicity (hereinafter referred to as CDC activity) and antibody-dependent cytotoxicity (hereinafter referred to as ADCC activity), and are useful for therapeutic applications. It is.
- a humanized antibody expression vector is an expression vector for animal cells into which genes encoding the C regions CH and CL of the human antibody are incorporated. It was constructed by inserting each of the encoding genes.
- the C region of a human antibody for example, the C region of any human antibody such as CT / 1 or C ⁇ 4 for a human antibody heavy chain and C ⁇ for a human antibody L chain can be used.
- the gene encoding the C region of the human antibody chromosomal DNA consisting of exons and introns can be used, and cDNA can also be used.
- the expression vector for animal cells any vector can be used as long as it can incorporate and express the gene encoding the human antibody C region.
- pAGE107 [Cytotechnology, 3, 133 (1990)]
- pAGE103 [J. Biochem., 101, 1307 (1987)]
- pHSG274 [Gene, 27, 223 (1984)]
- pKCR Proc. Natl. Acad. Sci. USA, 78, 1527 (1981)]
- pSGl ⁇ d2-4 [Cytotechnology, 4, 173 (1990):]
- the promoter and enhancer used in the expression vector for animal cells include the SV40 early promoter and enhancer [J. Biochem., 101, 1307 (1987)], the LTR promoter and the enhancer of Moroni murine leukemia virus [Biochem. Biophys. Res. Med., 149, 960 (198 7 )], and immunoglobulin heavy chain promoter [Cell, 41, 479 (1985)] and Enhanser [Cell, 33, 717 (1983)].
- the expression vector for the hen M antibody can be either the type in which the antibody H and L chains are present on separate vectors or the type in which the antibody is present on the same vector (tandem type).
- a vector for expressing a tandem humanized antibody in terms of ease of construction of an expression vector, ease of introduction into animal cells, and balance of expression levels of antibody H and L chains in animal cells. Is more preferable [J. Immunol. Methods, 167, 271 (1994)].
- Non-human animal antibodies for example, cDNAs encoding VH and VL of a mouse anti-human VEGF receptor Fit-1 monoclonal antibody are obtained as follows.
- the synthesized cDNA is inserted into a vector such as a phage or a plasmid to prepare a cDNA library.
- a recombinant phage or plasmid containing VH-encoding cDNA, and VL were obtained by using a C region or V region of a non-human animal antibody, for example, a mouse antibody as a probe. Isolate the recombinant phage or plasmid containing the desired cDNA.
- the entire nucleotide sequence of VH and VL of the target antibody on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence of VH and VL is deduced from the nucleotide sequence.
- An antibody expression vector can be constructed.
- a restriction enzyme recognition sequence for cloning cDNA encoding VH and VL of a non-human animal antibody is provided in advance of the gene encoding the CH and CL of the human antibody in the chimeric antibody expression vector.
- a human chimeric antibody expression vector can be produced by inserting a cDNA encoding the V region of an antibody of a non-human animal into this closing site via a synthetic DNA described below.
- Synthetic DNA consists of the nucleotide sequence at the 3 'end of the V region of an antibody of a non-human animal and the nucleotide sequence at the 5' end of the C region of a human antibody. It is manufactured using a DNA synthesizer so as to have
- VH and VL that form the antigen-binding site of the antibody are composed of four relatively conserved framework regions (hereinafter referred to as FR regions) and three sequence-rich complementary sequences that link them. Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, (1991); Sequences 'ob''proteins' ob. Immunological interest. ]. Each CDR amino acid sequence (CDR sequence) can be identified by comparing it with the amino acid sequence of the known antibody V region (Sequences of protein proteins of interest). (5) Construction of cDNA encoding V region of human CDR-grafted antibody
- CDNAs encoding VH and VL of the human CDR-grafted antibody can be obtained as follows.
- the FR amino acid sequence of the V region of the human antibody for grafting the CDR of the V region of the antibody of the target non-human animal is selected for each of VH and VL.
- the FR amino acid sequence of the V region of the human antibody any FR amino acid sequence of the V region of the human antibody can be used.
- the amino acid sequence of FR in the V region of a human antibody registered in the Protein Data Bank and the common amino acid sequence of each subgroup of FR in the V region of a human antibody are highly homologous to the amino acid sequence of the V region of the target non-human animal antibody, preferably 65. It is desirable to have homology of at least%.
- the DNA sequence encoding the amino acid sequence of FR in the V region of the selected human antibody and the DNA sequence encoding the amino acid sequence of the CDR in the V region of the antibody of the target non-human animal are ligated to obtain VH, Design a DNA sequence that encodes the amino acid sequence of each VL.
- PCR Polymerase Chain Reaction
- the amplified fragment is subcloned into an appropriate vector, its base sequence is determined, and a plasmid containing cDNA encoding the amino acid sequence of the V region of each chain of the target human CDR-grafted antibody is obtained.
- both sense and antisense is synthesized using synthetic DNA consisting of about 100 bases, and annealing and ligation are performed to obtain the amino acid sequence of the V region of each chain of the target human CDR-grafted antibody.
- synthetic DNA consisting of about 100 bases
- annealing and ligation are performed to obtain the amino acid sequence of the V region of each chain of the target human CDR-grafted antibody.
- a cDNA encoding the same can be constructed.
- a human CDR-grafted antibody has the activity of the original non-human animal by simply grafting only the CDR of the V region of the target non-human animal antibody between the FRs of the V region of the human antibody. It is known that the activity is lower than that of the antibody [BIO / TECHNO OGY, 9, 266 (1991)]. Therefore, of the amino acid sequence of FR in the V region of the human antibody, amino acid residues that are directly involved in binding to the antigen, amino acid residues that interact with amino acid residues of the CDR, or the three-dimensional structure of the antibody.
- Amino acid residues having a possibility of being involved in maintenance of a structure or the like have been modified into amino acid residues found in an antibody of a non-human animal to increase the activity.
- a method for producing a human CDR-grafted antibody applicable to any antibody has not yet been established, and at present, various trials and errors are required for each antibody.
- the modification of the FR amino acid sequence of the V region of the selected human antibody can be achieved by performing the PCR described in the above 2 (5) using various mutagenic primers.
- an amino acid sequence-modified vector After subcloning the amplified fragment after PCR into an appropriate vector, its base sequence is determined, and a vector containing the cDNA into which the desired mutation has been introduced (hereinafter referred to as an amino acid sequence-modified vector) is obtained.
- the modification of the amino acid sequence in a narrow region can be performed by a PCR mutagenesis method using a mutagenesis primer consisting of 20 to 35 bases. Specifically, a sense mutation primer and an antisense mutation primer consisting of 20 to 35 bases containing a DNA sequence encoding a modified amino acid residue are synthesized, and a cDNA encoding the amino acid sequence of the V region to be modified is prepared. Perform a two-step PCR using the plasmid containing After subcloning the final amplified fragment into an appropriate vector, its base sequence is determined, and an amino acid sequence-modified vector containing cDNA into which the desired mutation has been introduced is obtained.
- a human CDR-grafted antibody expression vector can be constructed.
- an appropriate restriction enzyme recognition sequence is added to the ends of the synthetic DNAs at the 5 ′ end and the 3 ′ end. By introduction, they can be inserted upstream of the gene encoding the C region of the desired human antibody so that they can be expressed in an appropriate form.
- the human chimeric antibody expression vector (2) above and the human CDR-grafted antibody expression vector (2) above or a modified vector thereof were used. It is introduced into COS-7 cells (ATCC CRL1651) to perform transient expression of a humanized antibody [Methods in Nucleic Acids Res., CRC Press, pp283 (1991)], and to measure its activity.
- Methods for introducing an expression vector into COS-7 cells include the DEAE-dextran method [Methods in Nucleic Acids Res., CRC Press, pp283 (1991)] and the lipofection method [Pro Natl. Acad. Sci. USA, 84, 7413. (1987)].
- the activity of the humanized antibody in the culture supernatant can be measured by the enzyme immunoassay (ELISA) described in 1 (5) above.
- ELISA enzyme immunoassay
- Transformation to stably produce a humanized antibody by introducing the human chimeric antibody expression vector of (2) and the human CDR-grafted antibody expression vector of (2) into appropriate host cells. You can get a strain.
- Examples of a method for introducing an expression vector into a host cell include a direct-portion method (Japanese Patent Application Laid-Open No. 257891/1990; Cytotechnology, 3, 133 (1990)).
- any cell can be used as long as it can express the humanized antibody.
- mouse SP2 / 0- Agl4 cells ATCC CRL 1581
- murine P3X63- A g 8.653 cells ATCC CRL 1580
- dihydrofolate reductase gene hereinafter, referred to as DHFR gene
- DHFR gene dihydrofolate reductase gene
- a transformant capable of stably producing a humanized antibody is selected on a RPMI1640 medium containing G418 and FCS according to the method disclosed in JP-A-2-2577891.
- the humanized antibody By culturing the obtained transformant in a medium, the humanized antibody can be produced and accumulated in the culture solution.
- the activity of the humanized antibody in the culture solution was determined by the method described in 1 (5) above. Measure more.
- the transformed strain can increase the amount of humanized antibody produced using a DHFR gene amplification system or the like according to the method disclosed in Japanese Patent Application Laid-Open No. 2-257891.
- the humanized antibody can be purified from the culture supernatant of the transformant using a protein A column (Chapter 8 of the Antibody's Laboratory Manual).
- other purification methods used for ordinary proteins can be used. For example, gel filtration, ion exchange chromatography, ultrafiltration and the like can be combined and purified.
- the molecular weight of the purified humanized antibody H-chain, L-chain or the entire antibody molecule can be determined by polyacrylamide gel electrophoresis (SDS-PAGE) [Nature, 227, 680 (1970)] or Western blotting (Antibody's antibody). Measure in 'Laboratory' Manual, Chapter 12).
- the reactivity of the purified humanized antibody and the binding activity of the humanized antibody to the VEGF receptor Fit-1 can be measured by the method described in 1 (5) above.
- An antibody fragment is generated by treating the above-mentioned antibody with an enzyme.
- the enzyme include papain and trypsin.
- DNA encoding the Fab, Fab, or F (ab,) 2 fragment of the anti-human VEGF receptor Fit-1 antibody is inserted into an expression vector for animal cells, and the vector is introduced into animal cells. It can be expressed to produce Fab, Fab, or F (ab ') 2 .
- the resulting antibody fragment can be purified by a combination of gel filtration, ion exchange, affinity chromatography, ultrafiltration and the like.
- the molecular weights of purified Fab, Fab, and F (ab,) 2 were determined by polyacrylamide gel electrophoresis (SDS-PAGE) [Nature, 227, 680 (1970)] or by Western blotting (Antibody's Laboratory). , Manual Chapter 12).
- Non-human animal antibody or human CDR transfer according to 2 (2), 2 (5) and 2 (6) above
- the expression vector of a single-chain antibody of a non-human animal antibody or a single-chain antibody of a human CDR-grafted antibody can be expressed.
- the single-chain antibody expression vector used herein any vector can be used as long as it can integrate and express cDNA encoding VH and VL of an antibody from a non-human animal or a human CDR-grafted antibody.
- any vector can be used as long as it can integrate and express cDNA encoding VH and VL of an antibody from a non-human animal or a human CDR-grafted antibody.
- AGE 107 [Cytotechnology, 3, 133 (1990)]
- Escherichia coli is used as a host for expressing single-chain antibodies.
- the single-chain antibody can be secreted extracellularly, transported to the polyplasma region, or retained in the cell.
- the cDNA encoding the single-chain antibody is ligated to the cDNA encoding VH and the cDNA encoding VL using synthetic DNA encoding a peptide linker having an appropriate restriction enzyme recognition sequence at both ends. Can be obtained. It is important that the linker peptide be optimized so that its addition does not interfere with the binding of VH and VL to the antigen, for example those shown by Pantoliano et al. [Biochemistry,, 10117 (1991)]. Alternatively, a modified version thereof can be used.
- a disulfide-stabilized antibody is a nucleotide sequence corresponding to one amino acid residue at an appropriate position in cDNA encoding VH and VL of a non-human animal antibody or cDNA encoding VH and VL of a human CDR-grafted antibody. Is modified to a nucleotide sequence corresponding to a cysteine residue, expressed and purified, and then formed to form a disulfide bond. Can be Amino acid residues can be changed to cysteine residues by the mutagenesis method using PCR described in 2 (5) above.
- a disulfide-stabilized antibody H chain expression vector and a disulfide-stabilized antibody L chain expression vector can be constructed.
- any vector can be used as long as it can integrate and express cDNA encoding modified VH and modified VL.
- pAGE107 [Cytotechnology, 3, 133 (1990)]
- pAGE103 [J. Biochem., 101, 1307 (1987)]
- pHSG274 [Gene, 27, 223 (1984)]
- pKCR Proc. Natl. Acad. Sci.
- an appropriate host is selected from Escherichia coli, yeast, animal cells, etc. Power that can be selected In that case, it is necessary to select an expression vector appropriate for each host.
- a disulfide-stabilized antibody can be secreted extracellularly, transported to the periplasmic region, or retained inside the cell.
- a transformed strain to be produced can be obtained.
- the expression of antibody fragments, single-chain antibodies, disulfide-stabilized antibody H chains or disulfide-stabilized antibody L chains contained in the culture supernatant, etc. was confirmed by the method described in 1 (5) above. can do.
- a single-chain antibody, a disulfide-stabilized antibody H chain or a disulfide-stabilized antibody chain can be achieved by a combination of known techniques. For example, If antibody fragments, single-chain antibodies, disulfide-stabilized antibody H chains or disulfide-stabilized antibody L chains are secreted into the medium, they can be concentrated by ultrafiltration, followed by various types of chromatography or gel filtration. It can be achieved by executing. Further, if the cells are transported to the periplasmic region of the host cell, the cells can be subjected to osmotic shock, concentrated by ultrafiltration, and then achieved by performing various types of chromatography or gel filtration. I can do it.
- Antibody fragments single-chain antibodies, disulfide-stabilized antibody H chains or disulfide-stabilized antibody L chains, which are insoluble and exist as granules (inclusion body), lyse cells and granules in a single cell. It can be achieved by repeating centrifugation and washing for separation, for example, solubilization with guanidine-hydrochloric acid, and then performing various chromatography or gel filtration chromatography.
- the purified single-chain antibody can be measured by the method described in 1 (5) or the like.
- the purified disulfide-stabilized antibody The H chain and the disulfide-stabilized antibody chain are mixed together, and a disulfide bond is formed by an operation that leads to an active structure [refolding operation, Molecular Immunology, 32, 249 (1995)].
- the active disulfide-stabilized antibody can be purified by antigen affinity chromatography or ion exchange chromatography or gel filtration.
- the activity of the disulfide-stabilized antibody can be measured by the method described in the above 1 (5) or the like.
- Peptides can also be used as derivatives of antibodies.
- a fusion antibody or fusion peptide in which an antibody or peptide is chemically bound to a toxin protein is prepared according to the method described in the literature [Anticancer Research, 11_, 2003 (1991); Nature Medicine, 3, 350 (1996)]. Can be made.
- a fusion antibody or peptide in which an antibody or peptide is bound to a protein such as a toxin, cytodynamic protein or enzyme by genetic engineering is described in Proc. Natl. Acad. Sci. USA, 93, 974 (1996); Proc. Natl. Acad. Sci. USA, 93, 7826 (1996)].
- a fusion antibody or fusion peptide in which an antibody or peptide is chemically bound to a low molecular weight anticancer agent can be prepared according to the method described in the literature [Science, 261_, 212 (1993)] and the like.
- These derivatives can be used for more effective diagnosis with less side effects by accumulating radioisotopes, toxins, proteins such as cytokins or enzymes, and low-molecular-weight drugs around the target tissue according to the specificity of the antibody molecule. It is expected to enable treatment.
- anti-VEGF receptor Flt-1 antibody, peptide, a fusion antibody thereof or a fusion peptide thereof, or a fusion peptide binds to the human VEGF receptor Fit-1, and acts through the effector activity of antibodies such as ADCC and CDC.
- ADCC and CDC antibodies
- the antibody, peptide, fusion antibody or drug containing the fusion peptide of the present invention can be administered alone as a therapeutic agent, but is usually one or more pharmacologically acceptable carriers. And provided as pharmaceutical preparations prepared by any of the methods well-known in the art of pharmacy.
- intravenous administration can be preferably used.
- Administration forms include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes and the like.
- Formulations suitable for oral administration include emulsions, syrups, capsules, tablets, powders, granules and the like.
- Liquid preparations such as emulsions and syrups include water, sugars such as sucrose, sorbitol, fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil, soybean oil, and P-hydroxy. It can be manufactured using preservatives such as benzoic acid esters and flavors such as strawberry flavor and peppermint as additives.
- Capsules, tablets, powders, granules, etc. include excipients such as lactose, glucose, sucrose, mannitol, disintegrants such as starch and sodium alginate, lubricants such as magnesium stearate, talc, polyvinyl alcohol, hydroxy It can be produced using a binder such as propylcellulose and gelatin, a surfactant such as a fatty acid ester, and a plasticizer such as glycerin as additives.
- Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.
- An injection is prepared using a carrier comprising a salt solution, a glucose solution, or a mixture of both.
- Suppositories are prepared using carriers such as cocoa butter, hydrogenated fats or carboxylic acids.
- Sprays are prepared using the antibody or peptide itself, or a carrier that does not irritate the oral and respiratory mucosa of the recipient and disperses the compound as fine particles to facilitate absorption.
- the carrier include lactose and glycerin.
- Formulations such as aerosols and dry powders are possible depending on the properties of the antibody or peptide and the carrier used.
- the components exemplified as additives for oral preparations can also be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc. Normally, it is 10 / g / kg to 8 mg / kg per day for an adult.
- the antibody or peptide against human VEGF receptor Flt-1 of the present invention may be used for the growth or metastasis of solid tumors such as breast cancer, prostate cancer, colorectal cancer, stomach cancer and lung cancer, arthritis in rheumatoid arthritis, diabetic retinopathy, premature infants It can be used as a diagnostic or therapeutic agent for diseases in which the disease progresses due to abnormal angiogenesis such as retinopathy and psoriasis.
- the antibody or peptide of the present invention has a neutralizing activity against human Fit-1, it inhibits the binding of human VEGF to Fit-1. In other words, it inhibits Flt_l autophosphorylation and Inhibits the migration of existing human vascular endothelial cells. Therefore, the pathology is caused by abnormal growth of solid tumors such as breast cancer, prostate cancer, colorectal cancer, stomach cancer, and lung cancer, or metastasis formation, abnormalities of angiogenesis such as arthritis, rheumatoid retinopathy, prematurity retinopathy and psoriasis in rheumatoid arthritis. Can be used as a therapeutic agent for diseases in which the disease progresses.
- the method for examining the antitumor effect of the antibody or peptide used in the present invention on various tumor cells includes an in vitro experiment, a method for measuring complement-dependent cytotoxicity (CDC activity), and an antibody-dependent cytotoxicity. (ADCC activity) and the like, and in vivo experiments include antitumor experiments using a tumor system in experimental animals such as mice.
- the present invention provides a method for immunologically detecting and quantifying cells expressing human VEGF receptor Fit-1 or human VEGF receptor Fit-1 on the surface of Itoda wrapping, and a method for detecting soluble human VEGF receptor Fit-1.
- Method for immunologically detecting and quantifying 1 method for inhibiting the binding of human VEGF to human VEGF receptor Fit-1; method for neutralizing the function of human VEGF receptor Flt-1; migration of endothelial cells
- Method for inhibiting 1 method for inhibiting the binding of human VEGF to human VEGF receptor Fit-1
- method for neutralizing the function of human VEGF receptor Flt-1 migration of endothelial cells
- immunologically detecting and quantifying cells expressing human VEGF receptor Fit-1, cells expressing human VEGF receptor Flt-1 or soluble human VEGF receptor Fit-1 Methods include immunohistochemical staining (ABC, CSA) such as immunofluorescence, immunoenzyme immunoassay (ELISA), radiolabeled immunoassay (RIA), immunohistochemistry, and immunocytochemistry. Etc.), Western plotting method, immunoprecipitation method, enzyme immunoassay described above, sandwich ELISA method [Monoclonal antibody experiment manual (Kodansha Scientific, 1987), seismic chemistry experiment course 5 Immunobiochemistry Research Methods (Tokyo Kagaku Doujin, 1986)].
- the fluorescent antibody method is an anti-immunoglobulin antibody or binding fragment that is obtained by reacting the antibody or peptide of the present invention with isolated cells or tissues and then labeling with a fluorescent substance such as fluorescin'isothiosinate (F1TC). After the reaction, the fluorescent dye is This is a method of measuring in one step.
- F1TC fluorescin'isothiosinate
- the immunoenzymatic antibody method refers to the separation of the antibody or peptide of the present invention into separated cells or lysates thereof, tissues or lysates thereof, cell culture supernatants, serum, pleural effusion, ascites, and eye fluid. Is reacted with an anti-immunoglobulin antibody or a binding fragment labeled with an enzyme such as peroxidase or biotin, and then the coloring dye is measured with an absorptiometer.
- the radioactive substance-labeled immunoassay refers to the reaction of the antibody of the present invention with isolated cells or their lysates, tissues or their lysates, cell culture supernatants, serum, pleural effusion, ascites, and eye fluid. Further, after reacting a radiolabeled anti-immunoglobulin antibody or a binding fragment, measurement is performed with a scintillation counter or the like.
- Immune cell staining and immunohistochemistry are defined as the steps of reacting an antibody or peptide of the present invention with isolated cells or tissues, and then using a fluorescent substance such as fluorescin'isothiosinate (FITC), peroxidase, or biotin. After reacting an anti-imnoglobulin antibody or a binding fragment labeled with an enzyme such as an enzyme, the reaction is observed using a microscope. In addition, the inhibitory activity of the binding between human VEGF and the human VEGF receptor Fit-1 was measured by a method for measuring the binding between a growth factor and a receptor. ] And the like, a VEGF-VEGF receptor Fit-1 binding inhibition test using the antibody of the present invention can be confirmed.
- FITC fluorescin'isothiosinate
- a scintillation counter or the like By reacting the antibody or peptide of the present invention simultaneously with VEGF labeled with a radioactive substance or the like, the activity of inhibiting the binding of VEGF labeled with a radioactive substance or the like to Flt-1 can be measured.
- the autophosphorylation inhibitory activity of the VEGF receptor Fit-1 is determined by a method such as the growth factor receptor autophosphorylation measurement method [Sequence Chemistry Laboratory Lecture Information transmission and cellular response (Tokyo Kagaku Dojin, 1986)]. It can be confirmed by conducting an autophosphorylation inhibition test of VEGF-VEGF receptor Fit-1 using an antibody or a peptide.
- VEGF is reacted with cells or tissues expressing Fit-1 and VEGF is bound.
- autophosphorylation of Fit-1 that is enhanced by the combination is detected by immunoprecipitation and Western blotting.
- By reacting the antibody or peptide of the present invention simultaneously with VEGF it is possible to measure the activity of inhibiting the autophosphorylation of Flt-l, which is enhanced by the binding of VEGF.
- the inhibitory activity of human VEGF can be measured by performing VEGF-dependent endothelial cell proliferation, migration, and tube formation tests [New Chemistry Laboratory Lecture 10 Blood vessels (endothelium and smooth muscle) (Tokyo Kagaku Dojin, 1991)] Can be confirmed by
- the VEGF-dependent growth test of vascular endothelial cells is a method in which vascular endothelial cells are reacted with VEGF, and the number of vascular endothelial cell growth-promoting activities that is enhanced by the binding of VEGF is measured.
- VEGF vascular endothelial growth-promoting activities that is enhanced by the binding of VEGF.
- the VEGF-dependent migration test of vascular endothelial cells is a method of reacting vascular endothelial cells with VEGF and observing, using a microscope, the vascular endothelial cell migration promoting activity that is enhanced by the binding of VEGF.
- By reacting the antibody or the peptide of the present invention simultaneously with VEGF it is possible to measure the activity of inhibiting the migration promoting activity of vascular endothelial cells which is enhanced by VEGF.
- the VEGF-dependent vascular endothelial cell tube formation test is a method in which vascular endothelial cells are reacted with VEGF, and the tube formation promoting activity of vascular endothelial cells, which is enhanced by the binding of VEGF, is observed using a microscope.
- VEGF vascular endothelial growth factor
- cells expressing the human VEGF receptor Fit-1 on the cell surface are prepared. After suspending cells as they are, and detaching adherent cells with trypsin EDTA, the cells are suspended in an immune cell staining buffer (PBS containing 1% BSA, 0.02% EDTA, 0.05% sodium azide), etc. 1 X 10 5 is dispensed into each ⁇ 2 X 1 0 6 pieces.
- an immune cell staining buffer PBS containing 1% BSA, 0.02% EDTA, 0.05% sodium azide
- Anti-human VEGF receptor obtained in (4) Culture supernatant of Fit-1 monoclonal antibody-producing hybridoma or culture supernatant of anti-human VEGF receptor Flt_l humanized antibody-producing transformant obtained in 2 (9), or 1 (6), 2 (9)
- immunize the purified antibody obtained in 3 (4) or biotin-labeled antibody by a known method (enzyme antibody method: interdisciplinary project 1985) to a concentration of 0.1 to 50 ⁇ g / ml.
- Culture supernatant of anti-human VEGF receptor Fit-1 monoclonal antibody-producing hybridoma obtained in 1 (4) or culture of anti-human VEGF receptor Fit-1 humanized antibody-producing transformant obtained in 2 (9) When reacting the supernatant or the purified antibody obtained in 1 (6), 2 (9) or 3 (4), wash the cells with a buffer solution for immunocytostaining, and then use fluorescence such as FITC or phycoerythrin. Dispense 50-500 ⁇ l of an immunocell staining buffer containing a dye-labeled anti-mouse immunoglobulin antibody, anti-rat immunoglobulin antibody, or anti-human immunoglobulin antibody at a concentration of about 0.1 to 50 ⁇ g / ml.
- reaction under ice-cooling for 30 minutes When the biotin-labeled antibody is reacted, 50-500 ⁇ l of streptavidin labeled with a fluorescent dye such as FITC or phycoerythrin is dispensed at 50-500 ⁇ l each, and the reaction is performed under ice-cooling for 30 minutes under light shielding. . After the reaction, wash well with immunobtaining cell staining buffer and analyze with a cell sorter.
- a fluorescent dye such as FITC or phycoerythrin
- NIH3T3-Flt_l human VEGF receptor Flt-1 expressing NIH3T3 cells
- control cells such as NIH3T3 cells
- NIH3T3-Neo NIH3T3 cells
- a reaction according to the labeling substance is performed.
- Methods for inhibiting the binding between human VEGF and the human VEGF receptor Fit-1 include the following methods.
- Dispense methanol into a 96-well MultiScreen-IP plate (96-well MultiScreen-IP Plate; manufactured by Millipore) at 100 ⁇ l / well to hydrophilize the PVDF membrane at the bottom of the plate.
- 50 ⁇ l of recombinant protein such as a fusion protein of human VEGF receptor Fit-1 or human VEGF receptor Flt_l and other proteins diluted with PBS to a concentration of 0.1 to 10 ⁇ g / ml was added to 50 ⁇ l.
- Methods for diagnosing diseases based on the growth or metastasis of solid tumors such as breast cancer, prostate cancer, colorectal cancer, stomach cancer, and lung cancer, and diseases in which the disease progresses due to abnormal angiogenesis, include humans present in cells or tissues of the subject.
- the above-described method for immunologically detecting or quantifying the VEGF receptor Flt_l using the antibody or the peptide of the present invention is mentioned.
- FIG. 1 is a view showing a construction step of plasmid pBS1732H.
- FIG. 2 is a view showing a construction step of plasmid pBS1732L.
- FIG. 3 is a view showing a construction process of plasmid PKANTEX1732H.
- FIG. 4 is a view showing a construction step of plasmid pKANTEX1732.
- FIG. 5 is a view showing a construction process of plasmid pBS1750H.
- FIG. 6 is a view showing a construction process of plasmid pBS1750L.
- FIG. 7 is a view showing a construction step of plasmid pKANTEX1750H.
- FIG. 8 is a view showing a construction step of plasmid pKANTEX1750.
- FIG. 9 is a diagram showing an electrophoresis pattern of purified anti-human VEGF receptor Flt_l human chimeric antibodies KM2532 and KM2550 by SDS-PAGE (using a 4 to 15% gradient gel).
- Lane 1 is a low molecular marker
- lane 2 is KM2532 under reducing conditions
- lane 3 is KM2550 under reducing conditions
- lane 4 is a high molecular marker
- lane 5 is KM2532 under non-reducing conditions
- lane 6 is non-reducing
- the migration pattern of KM2550 under each condition is shown.
- FIG. 10 shows the binding activity of purified anti-human VEGF receptor Flt-1 human chimeric antibodies KM2532 and KM2550 to soluble human VEGF receptor Fit-17N.
- A shows the results when the concentration of the soluble human VEGF receptor Fit-17N to be adsorbed on the plate was kept constant (1 ⁇ g / ml) and the concentration of the added human chimeric antibody was varied.
- the vertical axis shows the binding activity to the soluble human VEGF receptor Flt-17N, and the horizontal axis shows the concentration of the human chimeric antibody.
- ⁇ indicates the activity of KM2532, and ⁇ indicates the activity of KM2550, respectively.
- B can be adsorbed on the plate FIG.
- FIG. 9 shows the results obtained by measuring the binding activity of a constant concentration (10 ⁇ g / ml) of a human chimeric antibody by changing the concentration of soluble human VEGF receptor Flt — 17N.
- the vertical axis shows the binding activity to the soluble human VEGF receptor Flt-17N, and the horizontal axis shows the concentration of the soluble human VEGF receptor Fit-17N adsorbed on the plate.
- ⁇ indicates the activity of KM2532, and ⁇ indicates the activity of KM2550, respectively.
- FIG. 11 is a graph showing the activity of purified anti-human VEGF receptor Fit-1 human-type chimeric antibodies KM2532 and KM2550 for inhibiting the binding of human VEGF to human VEGF receptor Fit-1.
- ⁇ indicates the activity of KM1732
- ⁇ indicates the activity of KM1750
- ⁇ indicates the activity of KM2532
- the image indicates the activity of KM2550.
- FIG. 12 is a view showing a construction process of plasmid phKM1732HV0.
- FIG. 13 is a view showing a construction process of plasmid phKM1750HV0.
- FIG. 14 is a view showing a construction process of plasmid phKM1732LV0.
- FIG. 15 is a view showing a construction process of plasmid phKM1750LV0 (IV).
- FIG. 16 is a view showing a construction process of plasmid PKANTEX1732HV0.
- FIG. 17 is a view showing a construction step of plasmid pKANTEX1732HV0LV0.
- FIG. 18 is a view showing a plasmid pKANTEX1750HV0LV0 (IV).
- FIG. 19 is a view showing a construction step of plasmid pVL1393 / Flt 3N.
- FIG. 20 is a view showing a construction step of plasmid pVLl 393 / Flt 7N.
- FIG. 21 is a view showing a pattern of purified SDS polyacrylamide electrophoresis (using a 5-20% gradient gel) of Fit- 17N and Fit- 13N. From left, the migration patterns of the molecular weight markers, Flt-1 3N and Flt-17N are shown. Electrophoresis was performed under reducing conditions.
- FIG. 23 shows the results obtained by examining the binding reactivity of anti-human VEGF receptor Flt-1 monoclonal antibody by enzyme immunoassay.
- FIG. 24 shows the results of examining the activity of the anti-human VEGF receptor Fit-1 monoclonal antibody for inhibiting the binding between VEGF and human VEGF receptor Flt-1.
- Anti-human VEGF receptor Fit-1 monoclonal antibodies KM1732, KM1748 and 3 shows the results of examining the binding inhibitory activity of human VEGF and human VEGF receptor Fit-1 by M1750.
- FIG. 26 shows the results of examining the activity of the anti-human VEGF receptor Fit-1 monoclonal antibodies KM1732, KM1748 and M1750 for inhibiting the binding between human VEGF and human VEGF receptor Flt_l-expressing cells.
- Fig. 27 Reactivity of anti-human VEGF receptor Fit-1 monoclonal antibodies KM1730, KM1731, KM1732, KM1748 and KM1750 with human NIGF3 expressing Fit-1 cells NIH3T3-Fit-1 and control cells NIH3T3-Neo cells The results of analysis using a flow cytometer are shown.
- FIG. 28 shows the results of examining the reactivity of the anti-human VEGF receptor Fit-1 monoclonal antibody KM1737 with the human VEGF receptor Fit-1 by Western blotting.
- Lane 1 shows NIH3T3-Fit-1 cells
- lane 2 shows Western blotting of NIH3T3-Neo cells.
- Fig. 29 shows the results of examining the quantification system of soluble human VEGF receptor Fit-13N and FLT-17N using anti-human VEGF receptor Fit-1 monoclonal antibody KM1732 and biotinylated KM1730.
- Fig. 30 Fit-17N, a soluble human VEGF receptor and its derivative of anti-human VEGF receptor Fit-1 monoclonal antibody KM1732, KM1750, and anti-human VEGF receptor Fit-1 human chimeric antibody KM2532, K2550
- the results of examining the binding reactivity of Flt-13N, Flt-12N, Fit-17N.K2 and KDR7N by enzyme immunoassay are shown.
- Fig. 31 Soluble human VEGF receptor of anti-human VEGF receptor Fit-1 human chimeric antibody KM2532, K2550 and its derivatives Fit-17N, Fit-13N, Fit-12N, Fit-17N. The results obtained by examining the concentration-dependent binding reaction of K2 and KDR 7N by enzyme immunoassay are shown.
- FIG. 32 shows a schematic diagram of various derivatives of a soluble human VEGF receptor.
- FIG. 33 is a view showing a step of constructing plasmids phKMlO and V0 (I).
- FIG. 34 is a view showing a step of constructing plasmid pKANTEX1750HV0LV0 (I).
- FIG. 35 is a view showing a step of constructing plasmid phKM1750HV3.
- FIG. 36 is a view showing a step of constructing plasmid phKM50LV4.
- FIG. 37 is a view showing a step of constructing plasmid pKANTEX1750HV3LV0 (I).
- FIG. 38 is a view showing a step of constructing plasmid pKANTEX1750HV3V0 (IV).
- FIG. 39 is a view showing a step of constructing plasmid pKANTEX1750HV0LV4.
- FIG. 40 is a view showing a step of constructing plasmid pKANTEX1750HV3LV4.
- FIG. 9 is a diagram showing an electrophoresis pattern of a 15% gradient gel.
- Lanes 1 to 9 show electrophoresis patterns under non-reducing conditions
- lanes 10 to 19 show electrophoretic patterns under reducing conditions.
- Lanes 1 and 10 are high molecular weight markers
- lane 19 is low molecular weight marker
- lanes 2 and 11 are control antibodies KM8969
- lanes 3 and 12 are KM2550
- lanes 4 and 13 are KM8550
- lanes 5 and 14 are KM8551
- lanes 6 and 15 are KM8552
- lanes ⁇ and 16 are KM8553
- lanes 8 and 17 are
- FIG. 42 shows the binding activity of the anti-human VEGF receptor Fit-1 human chimeric antibody KM2550 and human CDR-grafted antibodies KM8550, M8551, KM8552, KM8553, KM8554, and KM8555 to the soluble human VEGF receptor Flt_l7N. is there.
- FIG 43 Anti-human VEGF receptor Fit-1 Human chimeric antibody KM2550 and human CDR-grafted antibody Various soluble human VEGF receptor derivatives of KM8550, KM8551, KM8552, KM8553, KM8554, K8555 Fit-1-7N, Fit-1 It is a figure which showed the binding activity with 3N, Fit-12N, Fit-17N.K2, KDR7N.
- FIG. 44 Anti-human VEGF receptor Fit-1 human chimeric antibody KM2550 and human CDR-grafted antibodies KM8550, K8551, KM8552, KM8553, KM8554, M8555 inhibit the binding inhibitory activity of human VEGF and human VEGF receptor Flt-1
- FIG. 44 Anti-human VEGF receptor Fit-1 human chimeric antibody KM2550 and human CDR-grafted antibodies KM8550, K8551, KM8552, KM8553, KM8554, M8555 inhibit the binding inhibitory activity of human VEGF and human VEGF receptor Flt-1
- FIG. 45 is a view showing the amino acid sequence of the H chain variable region of the anti-human VEGF receptor Fit-1 human chimeric antibody and CDR-grafted antibody.
- KM1750mouse is the amino acid sequence of the variable region of the H chain of KM1750
- KM1750HV0 is the amino acid sequence configured by inserting the CDR in the variable region of the H chain of KM1750 into the human framework
- KM1750HV3 is the amino acid sequence of KM1750HV0.
- the amino acid sequences obtained by partially substituting the amino acid sequence of the framework with the amino acid of KM1750mouse are shown.
- FIG. 46 is a view showing an amino acid sequence of an L chain variable region of an anti-human VEGF receptor Fit-1 human chimeric antibody and a CDR-grafted antibody.
- KM1750mouse is the amino acid sequence of the variable region of the light chain of KM1750
- KM1750LV0 (I) is the amino acid sequence composed of the CDR in the variable region of the light chain of KM1750 inserted into the human framework
- KM1750LV4 is the amino acid sequence composed of the CDR in the variable region of the light chain of KM1750 inserted into the human framework
- KM1750LV4 KM1750LV00
- FIG. 47 is a graph examining the activity of the anti-human VEGF receptor Fit-1 monoclonal antibodies KM1732 and KM1750 to inhibit the migration of VEGF-dependent human vascular endothelial cells HUVEC.
- Example 1 Using 5 ⁇ g of each of the KM1732 and KM1750 mRNAs obtained in Example 1 (1), cDNA Synthesis Kit (Pharmacia Biotech), and EcoR I at both ends according to the instruction manual attached to the kit. CDNAs each having a -Notl adapter were synthesized. Approximately 6 ⁇ g of each prepared cDNA is dissolved in sterile 10/1 water and fractionated by agarose gel electrophoresis to correspond to the heavy chain of IgG type antibody (hereinafter referred to as H chain). The 1.5 kb cDNA fragment and the approximately 1 kb cDNA fragment corresponding to the light chain (hereinafter referred to as L chain) About 0.1 ⁇ g was recovered.
- H chain heavy chain of IgG type antibody
- 0.1 ⁇ g of the cDNA fragment of about 1.5 kb and 0.1 ⁇ g of the cDNA fragment of about l.Okb were combined with the Lambda ZAPII Vector (Lambda ⁇ Vector cut with EcoRI and treated with Calf Intestine Alkaline Phosphatase : Stratagene (1 ⁇ g) is dissolved in 11.5 ⁇ l of T4 ligase buffer (Takara Shuzo), and 175 units of ⁇ 4 DNA ligase (Takara Shuzo) is added. For an additional 2 hours at room temperature.
- Each phage prepared in 1 (2) of Example 1 was immobilized on a nitrocellulose filter according to a conventional method (Molecular. Cloning, 2nd edition).
- C region the constant region of mouse immunoglobulin (hereinafter referred to as C region) according to the instruction manual attached to L direct nucleic acid labeling and detection systems (Amersham).
- H chain is a mouse C lcDNA fragment [Cell, 18.559 (1979)]
- L chain is a mouse C ⁇ cDNA fragment [Cell, 22, 197 (1980)] as a probe
- a phage clone was obtained.
- the phage clone was cloned into a plasmid according to the instruction manual attached to Lambda ZAPII Vector (Stratagene).
- pBluescriptSK (-) was converted to the recombinant flop finally containing cDNA encoding the L chain of KM 17 32 recombinant plasmid KM 1732HA2 containing cDNA encoding the H chain of and KM 1732 plasmid KM1732L2- 1, KM1750 Recombinant plasmids KM1750H2-1 and KM1750L3-1 containing cDNA encoding the L chain of KM 1750 were obtained, respectively.
- E. coli XL1-Blue with recombinant plasmid KM 1732L2-1 E. coli XL1-Blue with MRF7KM1732L2-U recombinant plasmid 1750H2-1
- E. coli XL1-Blue having RF7K 1750H2-1 and recombinant plasmid KM1750L3-1
- the E. coli strain having MRF7KM1750L3-1 has FERM BP-6354, FERM BP-6352, FERM BP-6353, and FERM BP-6355, respectively.
- FERM BP-6354 FERM BP-6354
- FERM BP-6352 FERM BP-6352
- FERM BP-6353 FERM BP-6355
- V region The nucleotide sequence of the variable region (hereinafter referred to as V region) of the cDNA encoding the H chain and L chain of each anti-human VEGF receptor Fit-1 mouse monoclonal antibody obtained in 1 (3) of Example 1 was determined. Using 0.1 / g of the obtained plasmid, BigDye Terminator Cycle
- VH V region of the H chain
- VL V region of the L chain
- SEQ ID NO: 1 shows the nucleotide sequence of KM1732 VH
- SEQ ID NO: 2 shows the nucleotide sequence of KM1732
- SEQ ID NO: 3 shows the nucleotide sequence of KM1750
- SEQ ID NO: 4 shows the nucleotide sequence of VL of KM1750
- SEQ ID NO: 86 shows the VH of KM1732
- SEQ ID NO: 88 shows the amino acid sequence of KM1750 VH
- SEQ ID NO: 89 shows the amino acid sequence of KM1750 VL.
- Anti-human VEGF receptor Flt_l mouse having neutralizing activity against human VEGF receptor Fit-1
- Mouse anti-human VEGF receptor Fit-1 chimeric antibodies KM2532 and KM2550 derived from monoclonal antibodies KM1732 and KM1750 as follows: It was manufactured.
- the expression vector pKANTEX1732 was constructed as follows.
- the the reflected reaction solution was precipitated with ethanol, 50 mM Tris - HCl ( ⁇ ⁇ 7 ⁇ 5), lOOmM sodium chloride, LOMM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X-100 consists of buffer 10 mu In addition to 1, 10 units of a restriction enzyme NotK (Takara Shuzo) were added and reacted at 37 ° C. for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis.
- plasmid KM1732HA2 is buffered with 20 mM Tris-acetic acid (pH 7.9), ⁇ magnesium acetate, 50 mM potassium acetate, ImM DTT and 100 ⁇ g / ml bovine serum albumin (hereinafter referred to as BSA).
- BSA bovine serum albumin
- 10 units of a restriction enzyme NlalV manufactured by Ngrand Biolabs was further added and reacted at 37 ° C. for 1 hour.
- the reaction solution was precipitated with ethanol, and added to 10 ⁇ l of a buffer solution consisting of 50 mM Tris-hydrochloric acid (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X_100. Further, 10 units of restriction enzyme Notl (Takara Shuzo Co., Ltd.) was added and reacted at 37 ° C for 1 hour. The reaction mixture was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of a 0.41 kb NlalV-Notl fragment was recovered.
- a buffer solution consisting of 50 mM Tris-hydrochloric acid (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X_100. Further, 10 units of restriction enzyme Notl (Takara Shu
- a synthetic DNA having the nucleotide sequence of SEQ ID NO: 17 or 18 was synthesized (Saddy 1. 0.3 ⁇ g of each synthetic DNA was added to 15 ⁇ l of sterilized water, and heated at 65 ° C. for 5 minutes. After leaving the reaction solution at room temperature for 30 minutes, 2 ⁇ l of 10-fold buffer [500 mM Tris-hydrochloric acid (pH7.6), 100 mM magnesium chloride, 50 m DTT] and 2 ⁇ l of 10 mM ATP were added, and further 10 units were added. ⁇ 4 polynucleotide kinase (Takara Shuzo) was added and reacted at 37 ° C. for 30 minutes to phosphorylate the 5 ′ end.
- 0.1 ⁇ g of Apa-Notl fragment derived from plasmid pBluescript SK (-) obtained above, 0.1 ⁇ g of NlalV-Notl fragment derived from plasmid KM 1732HA2, and 0.05 ⁇ g of phosphorylated synthetic DNA were sterilized in a total volume of 10 ⁇ l.
- ligation was performed using DNA ligation Kit Ver.2 (Takara Shuzo) according to the instruction manual.
- the recombinant plasmid DNA solution thus obtained was used to transform Escherichia coli DH5 ⁇ strain (manufactured by Toyobo) to obtain the plasmid pBS1732H shown in FIG.
- the reaction solution was fractionated by agarose gel electrophoresis, and about 2 ⁇ g of an EcoRI-Spll fragment of about 2.95 kb was recovered.
- 5 ⁇ g of plasmid KM 1732-2 was added to 10 ⁇ l of a buffer solution consisting of 10 mM Tris-HCl (pH 7.5), 100 mM magnesium chloride, and ImM DTT, and an additional 10 units of restriction enzyme MboII (Toyo (Manufactured by Spinning Co., Ltd.) and reacted at 37 ° C. for 1 hour.
- the reaction ethanolate was Nord precipitate, 50 mM Tris - HCl (P H7.5), lOOmM sodium chloride, 10 mM chloride magnetic Shiumu, in addition to the LMM DTT force becomes buffer 10 mu 1, further 10 units of a restriction enzyme EcoRI (Takara (Manufactured by Shuzo) and reacted at 37 ° C for 1 hour.
- the reaction solution was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of a boII-EcoRI fragment of about 0.38 kb was recovered.
- 0.1 ⁇ g of the EcoRI-SplI fragment derived from the plasmid phKM1259LV0 obtained above, 0.1 ⁇ g of the EcoRI fragment of the plasmid KM1732L2-1 and 0.05 ⁇ g of phosphorylated synthetic DNA were added to a total volume of 10 ⁇ l of sterilized water. Ligation was performed using DNA ligation Kit Ver.2 (Takara Shuzo) according to the instruction manual. Escherichia coli DH5 ⁇ strain (manufactured by Toyobo Co., Ltd.) was transformed using the recombinant plasmid DNA solution obtained in this manner, and plasmid pBS1732L shown in FIG. 2 was obtained.
- 3 / g of the humanized antibody expression vector No. 93 was added to 10 ⁇ l of a buffer solution containing lOmM Tris-HCl ( ⁇ 7.5), 10 mM magnesium chloride and ImM DTT, and 10 units of the restriction enzyme Apal ( (Takara Shuzo) was added and reacted at 37 ° C for 1 hour.
- the reaction solution was precipitated with ethanol, and a buffer solution consisting of 50 mM Tris-hydrochloric acid (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X-100 was used.
- the reaction mixture was precipitated with ethanol and dissolved in 10 n 1 of a buffer consisting of 50 mM Tris-HCl (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ral BSA and 0.01% Triton X-100.
- 10 units of a restriction enzyme NotK (Takara Shuzo) was further added and reacted at 37 ° C for 1 hour.
- the reaction solution was fractionated by agarose gel electrophoresis, and about 0.46 kb Apa Notl fragment was recovered in an amount of about 0.5 ⁇ g.
- the antibody expression vector pKANTEX1750 was constructed as follows.
- the reaction solution was precipitated with ethanol, and the solution was diluted to 10 ⁇ l of a buffer solution containing 50 mM Tris-hydrochloric acid (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X-100.
- 10 units of Notl manufactured by Takara Shuzo Co., Ltd.
- the reaction solution was subjected to agarose gel electrophoresis. After fractionation, about 0.5 ⁇ g of an approximately 0.41 kb Av26I-Notl fragment was recovered.
- ligation was performed using DNA ligation Kit Ver.2 (Takara Shuzo) according to the instruction manual.
- Escherichia coli DH5 ⁇ strain (manufactured by Toyobo Co., Ltd.) was transformed using the recombinant plasmid DNA solution obtained in this manner to obtain a plasmid PBS1750H shown in FIG.
- plasmid KM1750L3-1 was added to 10 ⁇ l of a buffer consisting of 100 mM Tris-HCl (pH 8.8), 440 mM sodium chloride, 12 mM magnesium chloride, 14 mM 2-mercaptoethanol, and 200 ⁇ g / ml BSA.
- 10 units of a restriction enzyme Maell (Boehringer 1. Mannheim) was further added and reacted at 50 ° C. for 1 hour.
- the reaction mixture was precipitated with ethanol, added to 50 mM Tris-hydrochloric acid (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, 10 ⁇ l of ImM DTT buffer, and 10 units of restriction enzyme EcoRI (Takara Shuzo). And reacted at 37 ° C for 1 hour.
- the reaction mixture was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of a Maell-EcoRI fragment of about 0.38 kb was recovered.
- the reaction market shares ethanol precipitation, 50 mM Tris - HCl ( ⁇ ⁇ 7 ⁇ 5), lOOmM sodium chloride, 10 mM chloride mug Neshiumu, lmM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X - 100 force becomes buffer 10
- 10 units of Notl manufactured by Takara Shuzo
- the reaction solution was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of an Apal-Notl fragment of about 0.46 kb was recovered.
- PKANTEX 1732 and pKANTEX 1750 were introduced by electroporation [Cytotechnology, ⁇ 133 (1990)] according to the method of Miyachi et al.
- dienecin (hereinafter referred to as G418, manufactured by Gibco) was added to a concentration of 0.5 mg / ml, and the cells were further cultured for 1 to 2 weeks. G418 resistant transformant colonies appeared and the culture supernatant was recovered from the confluent gel.
- the activity of the anti-human VEGF receptor Fit-1 human chimeric antibody in the supernatant was determined as follows. It was measured by immunoassay.
- the soluble human VEGF receptor Fit-17N was prepared according to the method of Tanaka et al. [Japanese Journal of Cancer Research, 88 ⁇ 867 (1997)]. Dispense 1 ⁇ g / ml soluble human VEGF receptor Fit-17N diluted with PBS into a 96-well EIA plate (manufactured by Glyner) at 50 ⁇ 1 / well, and add 4 ⁇ C It was left to adsorb. After washing with PBS, 100 ⁇ l / well of PBS containing 1% BSA (hereinafter referred to as 1% BSA-PBS) was added and reacted at room temperature for 1 hour to block the remaining active groups.
- 1% BSA-PBS PBS containing 1% BSA
- MTX nM methotrexate
- transformants showing activity further increase the MTX concentration to 100 nM and 200 nM by the same culturing method as above, and use RPMI1640-FCS (10) medium containing 0.5 mg / ml G418 and 200 nM MTX.
- a transformant capable of growing and highly producing an anti-human VEGF receptor Fit-1 human chimeric antibody was obtained.
- the resulting transformant was cloned twice by the limiting dilution method to obtain a final transformed anti-human VEGF receptor Fit-1 human chimeric antibody-producing transformant cell line.
- a transformed cell line obtained by introducing the expression vector # 32 that is, a transformed cell line that produces an anti-human VEGF receptor Fit-1 human chimeric antibody derived from the anti-human VEGF receptor Fit-1 mouse monoclonal antibody KM1732
- An example thereof is KM2532, and the anti-human VEGF receptor Flt-II human chimeric antibody produced by it is named KM2532.
- a transformed cell line obtained by introducing the expression vector pKANTEX1750 that is, a transformant that produces an anti-human VEGF receptor Fit-1 human chimeric antibody derived from the anti-human VEGF receptor Fit-1 mouse monoclonal antibody KM1750
- KM2550 the anti-human VEGF receptor Fit-1 human chimeric antibody produced by it is named KM2550.
- the productivity of the anti-human VEGF receptor Fit-1 human chimeric antibody of each of the obtained transformed cell clones was about 5 ⁇ g / 10 6 cells / 24 hours.
- the cells were suspended at a concentration of 1 to 2 ⁇ 10 5 cells / ml, and 200 ml of the suspension was dispensed into 175 cm 2 flasks (manufactured by Grainer Co., Ltd.) in total of 5 cells.
- the cells were cultured in a 5% CO 2 incubator at 37 ° C. for 5 to 7 days. When the cells became confluent, about 1.0 L of each culture supernatant was collected.
- the purified anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were analyzed by SDS-PAGE. SDS-PAGE followed a known method [Anticancer Research, 12, 1121 (1992)]. The gel used was a 5-20% gradient gel (manufactured by Atoichi Co., Ltd.).
- the molecular weight of the gel was low molecular weight protein molecular weight marker “Daiichi” II, and high molecular weight protein molecular weight marker “Daiichi” 111 ( Under a reducing and non-reducing condition, 2.5 ⁇ g of protein per lane of anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were used under reducing and non-reducing conditions, respectively. Electrophoresed and stained with Coomassie Brilliant Blue. The results are shown in FIG.
- the human chimeric antibodies KM2532 and KM2550 showed an IgG band at a molecular weight of about 150 kDa, and under reducing conditions, an H-chain band power of about 50 kDa and an L-chain of about 25 kDa. A band was observed.
- the IgG type antibody breaks the intermolecular disulfide bond and breaks down into two heavy and light chains, respectively.
- the molecular weight is composed of two heavy and short chains, respectively. Consistent with its existence as a 150 kilodalton molecule, a human chimera Antibodies KM2532 and KM2550 were shown to be antibody molecules with the correct structure.
- the binding activity of the purified anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 to the human VEGF receptor Fit-1 was confirmed according to the following procedure.
- Soluble human Fit- 17N was prepared according to the method of Tanaka et al. [Japanese Journal of Cancer Research, 88, 867 (1997)].
- the amount of soluble human Fit-17N to be adsorbed to a 96-well EIA plate was fixed using enzyme immunoassay, and the binding activity was examined by changing the concentration of the added human chimeric antibody.
- 1% BSA-PBS was discarded, and 0.152 to 333 ng / ml of purified anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were dispensed at 50 1 / well and allowed to react at room temperature for 1 hour. After washing with 0.05% tween-PBS, a peroxidase-labeled anti-human IgG antibody (manufactured by American Corex) diluted 3000 times with 1% BSA_PBS was added at 50 1 / well, and reacted at room temperature for 1 hour.
- ABTS substrate solution [2.2-azinobis (3-ethylbenzothiazol-6-sulfonic acid) ammonium] at 50 ⁇ l / well to develop color, and measure absorbance at OD415nm. The measurement was carried out using E max (Molekiura I, manufactured by Devices).
- the results are shown in FIG.
- the binding activities of the anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were almost the same.
- the binding activity of the human chimeric antibody was examined by changing the amount of soluble human Fit-17N adsorbed on a 96-well EIA plate using enzyme immunoassay. Dispense 0.04 to 10 ⁇ g / ml soluble human VEGF receptor Fit-17N diluted in PBS at 50 ⁇ l / well into a 96-well BIA plate (Glyna) at 4 ° C. ⁇ ⁇ Leave and let it adsorb. With PBS After washing, 1% BSA-PBS was reacted with 100 ⁇ l / Derka syrup at room temperature for 1 hour to block the remaining active groups.
- 1% BSA_PBS was discarded and 10 ⁇ g / ml of purified anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were dispensed at 50 // 1 / well and reacted at room temperature for 1 hour. .
- a peroxidase-labeled anti-human IgG antibody manufactured by American Corex
- 1% BSA-PBS was added at 50 ⁇ l / well and allowed to react at room temperature for 1 hour.
- the ABTS substrate solution [2.2-azinobis (3-ethylpentazothiazol-6-sulfonic acid) ammonium] was added at 50 ⁇ l / well to develop the color. Absorbance was measured using E max (Molequiura I 'Devices).
- the result is shown in FIG. 10 (B).
- the anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 showed binding activity depending on the concentration of the soluble human VEGF receptor Fit- 17 adsorbed on the plate.
- the binding activities of the anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were almost the same.
- the activity of the anti-human VEGF receptor Fit-1 human chimeric antibody to inhibit the binding between human VEGF and human VEGF receptor Fit-1 was examined as follows. Methanol was dispensed into a 96-well 'Multiscreen-IP plate (Millipore) at 100 n1 / well to hydrophilize the PVDF membrane at the bottom of the plate. After washing with water, soluble human VEGF receptor Fit-17N diluted to a concentration of 0.2 ⁇ g / ml with PBS was dispensed at 50 ⁇ l / well, and allowed to stand at 4 ° C for adsorption. .
- 1% BSA-PBS was added in an amount of 50 ⁇ l / well, and reacted at room temperature for 1 hour to block the remaining active groups.
- anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 have the same binding inhibitory activity of human VEGF and human VEGF receptor Fit-1 as anti-human VEGF receptor Fit-1 mouse monoclonal antibodies KM1732 and KM1750. It was shown that the human chimeric antibody retained the activity of the mouse monoclonal antibody.
- Soluble human VEGF receptor KDR 7N and soluble human VEGF receptor chimeric protein Fit-17N.K2 were prepared as follows.
- a soluble human VEGF receptor KDR fragment (hereinafter referred to as a soluble human VEGF receptor KDR 7N) corresponding to 19 amino acids constituting the signal peptide of human VEGF receptor KDR and the 738th amino acid from the N-terminal amino acid of the mature form, and a linker
- a vector for expressing the derived 2-amino acid residue was prepared by the following procedure.
- the soluble human VEGF receptor KDR 7N is composed of seven immunoglobulin-like sites from the N-terminal side of the extracellular region of the soluble human VEGF receptor KDR.
- pUC-KDR CDNA clone encoding full-length cDNA of human VEGF receptor KDR B CMG S-Neo-KDR [Cell Growth & Differentiation 7, 213 (1996)] is cut with EcoRI to encode extracellular and membrane-bound regions of DR
- a pUC-KDR was prepared by incorporating the approximately 2.8 kb fragment into the EcoRI site of pUC18.
- pUC-KDR was digested with Xhol, treated with Klenow, and inserted with Xbal linker (SEQ ID NO: 57) to prepare pUC-KDR-Xb.
- pBS-KDR-Xb-S After inserting the Xbal-BamHI (2.3 kbp) fragment of pUC-KDR-Xb into the Xbal / BamHI site of pBluescriptll KS (+), a Sphl-BamHI (5.2 kbp) fragment was prepared, and a synthetic linker containing a SnaBI site ( SEQ ID NO: 58 and SEQ ID NO: 59) were used to prepare pBS-KDR-Xb-S.
- pBS-KDR-Xb-S was cut with SnaBI / BamHI, and a synthetic linker (SEQ ID NO: 60 and SEQ ID NO: 61) containing a stop codon and a Notl site was incorporated to prepare pBS-KDR (Xb) -SN. .
- an oligonucleotide consisting of 56 bases SEQ ID NO: 62
- a site-directed mutagenesis kit MutanK (Takara Shuzo) were used according to the manual attached to Takara Shuzo site-directed mutagenesis kit MutanK.
- perform site-directed mutagenesis, Fit- 1 extracellular region second I Takeno immunoglobulin-like site and the region coding is deletion mutant Fit- 1 plasmid carrying a gene of (P M 13- fh, - D2N ) was prepared.
- a DNA fragment encoding the site was recovered.
- the DNA fragment Cleavage with Narl / Kpnl yielded a 340 bp Narl / Kpnl fragment.
- the DNA fragment and the Smal / Narl (0.5 kb) fragment of pM13-flt'-D2N were inserted into the Smal / pnl site of pBluescriptll to prepare pBSfit-1'-KDR2N.
- each of the obtained recombinant viruses was propagated by the following procedure.
- the virus titer of the obtained recombinant virus solution was calculated by the method described in the Bakuguchi Gold Starter Kit 'Manual (manufactured by Pharmingen).
- a medium containing [agagar plaque 'Agarplaque Agarose', manufactured by Pharmingen] (Sterile lml of 5% agarplaque plus' agagarose aqueous solution and 4ml of TMN-FH Insect Medium) are mixed and kept at 42 ° C.
- vinyl tape was wrapped around a Petri dish to prevent drying, the dish was placed in a sealable plastic container, and cultured at 27 ° C for 6 days.
- each of the recombinant virus solutions contained about 1 ⁇ 10 7 plaque forming units (hereinafter, referred to as PFU) / ml of virus.
- PFU plaque forming units
- the collected purified fraction was concentrated using Centriprep 10 (manufactured by Amicon), and 4.8 ml of a solution of soluble human VEGF receptor KDR 7N (protein concentration: 815 ⁇ g / ml, purity: 70-80%) Obtained.
- the soluble human VEGF receptor chimeric protein Fit- 17N.2 was purified as follows.
- the column was filled with about 20 ml of heparin mono-Sepharose CL-6B Ge / re [Phanoremasia 'Pharmacia Biotech AB] and 0.5 ml / 100 ml of 20 mM Tris-HCl (pH 7.5) buffer. The column was washed at a flow rate of 1 minute. After washing, 900 ml of the culture solution containing the soluble human VEGF receptor chimeric protein Fit-17N.K2 prepared as described above was passed through a heparin-sepharose CL-6B column at a flow rate of 0.5 ml / min.
- the protein contained in each fraction was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and 50 to 70 ml of the fraction containing the soluble human VEGF receptor chimeric protein Fit- 17N.K2 was collected, and centrifuged. It was concentrated using Librep 10 (manufactured by Amicon). After concentration, 5.8 ml of each of the soluble human VEGF receptor chimeric protein Fit- 17N.K2 was obtained as a solution (protein concentration: 588 ⁇ g / ml, purity: 65 to 75%).
- Soluble human VEGF receptor Fit-17N (corresponding to the 750th position from the N-terminal amino acid including the signal sequence), soluble human VEGF receptor Flt-13N (corresponding to the 338th position from the N-terminal amino acid including the signal sequence), Soluble human VEGF receptor Fit-12N (corresponding to the 223rd amino acid from the N-terminal amino acid including the signal sequence) was prepared according to the method of Tanaka et al. [Japanese Journal of Cancer Research, 88, 867 (1997)].
- Soluble human receptor KDR 7N (including the signal sequence, equivalent to position 738 from the N-terminal amino acid), soluble human VEGF receptor chimeric protein Fit- 17N.2 (amino acids 100-204 of human Fit- 17N) was converted to amino acids 95 to 199 of human KDR via a linker) according to (6-5).
- FIG. 32 shows a schematic diagram of various derivatives of the soluble human VEGF receptor used in the experiment.
- the reactivity of the anti-human VEGF receptor Fit-1 mouse monoclonal antibody M1732, KM1750 and the anti-human VEGF receptor Fit-1 human chimeric antibody KM2532, KM2550 were compared using an enzyme immunoassay. Transfer 4 ⁇ g / ml of Flt-17N, Flt-1 3N, Flt-1 2N, Flt-1 7N.K2, and KDR 7N diluted with PBS to a 96-well E1A plate (Glyna). Each was dispensed at 50 ⁇ l / ⁇ , and allowed to stand overnight at 4 ° C. for adsorption.
- 1% BSA-PBS was allowed to react at 100 ⁇ l / perker nutrient at room temperature for 1 hour to block remaining active groups. Discard 1% BSA-PBS, 0.1 g / ml purified anti-human VEGF receptor Fit-1 mouse monoclonal antibody ⁇ 32 or KM1750, or purified anti-human VEGF receptor Fit-1 human chimeric antibody KM2532 or KM2550 was dispensed at 50 / z1 / well and allowed to react at room temperature for 1 hour.
- ABTS substrate solution [2.2-azinobis (3-ethylbenzothiazole-6-sulfonic acid) ) Ammonia] was added at 50 ⁇ l / well to develop color, and the absorbance at OD 4 15 mn was measured using E max (Molecular 'Devices).
- KM2550 (Fit-17N, Fit-13N, Fit-12N) did not bind to Fit-17N.K2 or KDR7N. Therefore, anti-human VEGF receptor Fit-1 mouse monoclonal
- the epitopes recognized by the antibodies KM1732 and KM1750 and the anti-human VBGF receptor Fit-1 human chimeric antibody KM2532 and K2550 must be contained in the region from the N-terminal amino acid 100 to 204 of the human Fit-1 It has been shown.
- 1% BSA-PBS was added at 100 ⁇ l / well, and reacted at room temperature for 1 hour to block the remaining active groups.
- 1% BSA-PBS was discarded, and 0.0152 to 100 ng / ml of purified anti-human VEGF receptor Fit-1 human chimeric antibody KM2532 or KM2550 was dispensed at 50 ⁇ l / mL and allowed to react at room temperature for 1 hour. .
- 1% BSA-PBS was added in an amount of 100 ⁇ l / ml, and reacted at room temperature for 1 hour to block the remaining active groups.
- 1% BSA-PBS was discarded, and 5 ⁇ g / ml of a purified anti-human VEGF receptor Flt-1 human chimeric antibody KM2532 or KM2550 was dispensed with 5 Q ⁇ l / well, respectively, and allowed to react at room temperature for 1 hour.
- a peroxidase-labeled anti-human IgG antibody (manufactured by American Corex) diluted 3000-fold with 1% BSA-PBS was added at 50 ⁇ l / well, and reacted at room temperature for 1 hour.
- the ABTS substrate solution [2.2-azinobis (3-ethylbenzothiazole-6-sulfonic acid) ammonium] was added at 50 ⁇ l / well to develop color, and the absorbance at OD415mn was measured at E max ( (Molecular Devices, Inc.).
- Anti-human VEGF receptor Fit-1 human chimeric antibody KM2532, M2550 shows binding activity depending on the concentration of soluble human VEGF receptor Fit-17N, Flt-1 3N, Flt-1 2N adsorbed on the plate, It did not react with Flt-17N.K2 or KDR7N.
- the binding activities of the anti-human VEGF receptor Fit-1 human chimeric antibodies KM2532 and KM2550 were almost the same.
- Anti-human VEGF receptor Fit-1 mouse with neutralizing activity against human VEGF receptor Fit-1 Mouse monoclonal antibody KM1732, M1750 and anti-human VEGF receptor Fit-1 Human chimeric antibodies KM2532, KM2550 With anti-human VEGF receptor Fit-1 human CDR Implanted antibodies were produced as follows.
- VH of various known human antibodies Were classified into subgroups I to III (HSG I to III) based on the homology of their amino acid sequences, and a common sequence was identified for each subgroup. Therefore, based on these consensus sequences, the amino acid sequence of VH of the anti-human VEGF receptor Flt-1 human CDR-grafted antibody was designed.
- the final concentration of each synthesized DNA was 0.1 // M 200 ⁇ M dNTP (Takara Shuzo), 0.5 ⁇ M 13primer RV (Takara Shuzo), 0.5 ⁇ M 13primer M4 (Takara Shuzo) and 2.5 units of TaKaRa Ex Taq DNA polymerase —Takara Shuzo
- the reaction solution was treated using Q1A quick PCR Purification Kit (manufactured by Qiagen) according to the attached instructions, purified and eluted with 20 ⁇ l of sterile water. Next, the obtained eluate was added to 30 ⁇ l of a buffer solution consisting of 10 mM Tris-hydrochloric acid (pH 7.5), 10 mM magnesium chloride and ImM DTT, and 20 units of the restriction enzyme Apal (Takara Shuzo) was further added. The reaction was performed at 37 ° C for 1 hour.
- the reaction solution was precipitated with ethanol, and 10 mM buffer solution consisting of 50 mM Tris-HCl (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, ImM DTT, 100 ⁇ g / ml BSA and 0.01% Triton X-100 was used.
- 10 units of restriction enzyme N'otI (Takara Shuzo) was further added and reacted at 37 ° C. for 1 hour.
- the reaction solution was fractionated by agarose gel electrophoresis, and about 0.44 kb of Apa Notl fragment of about 0.44 kb was recovered.
- the ligation was performed using DNA ligation Kit Ver.2 (Takara Shuzo) according to the instruction manual.
- Escherichia coli DH5 ⁇ strain manufactured by Toyobo Co., Ltd. was transformed using the recombinant plasmid DNA solution thus obtained.
- Each plasmid was prepared from 10 transformed Escherichia coli, and the nucleotide sequence was determined according to the method described in Section 1 (4) of Example 1. As a result, the result was shown in FIG. 12 containing cDNA encoding the amino acid sequence of interest.
- the plasmid phKM1732HV0 was obtained.
- the nucleotide sequence of VH (hereinafter referred to as 1732HV0) of the anti-human VEGF receptor Fit-1 human CDR-grafted antibody contained in ph M1732HV0 is shown in SEQ ID NO: 31 and the amino acid sequence is shown in SEQ ID NO: 90.
- Anti-human VEGF receptor contained in P hKM1750HV0 Fit- 1 human CDR-grafted antibody VH showed the nucleotide sequence SEQ ID NO: 38 and amino acid sequences (hereinafter, referred to as 1750HV0) in SEQ ID NO: 91.
- Hikbat et al. Classified the VL of various known human antibodies into subgunes 1 to iV (HSGl to [V]) based on the homology of their amino acid sequences, and identified a common sequence for each subgunle. Therefore, the amino acid sequence of VL of the anti-human VEGF receptor Flt-1 human CDR-grafted antibody was designed based on those consensus sequences. First, in order to select a consensus sequence as a basis, the amino acid sequence of the FR of the consensus sequence of the VL of the human antibody of each subgroup and the FR sequence of the VL of the anti-human VEGF receptor Flt-1 mouse monoclonal antibody KM1732 and KM1750 were selected. The homology with the amino acid sequence was examined (Table 2).
- the reaction solution was treated using QIA quick PCR Purification Kit (manufactured by Qiagen) according to the attached instructions, purified with 20 ⁇ l of sterilized water, and eluted. Next, the obtained eluate was added to 50m Tris-hydrochloric acid (pH 7.5), lOOmM sodium chloride, 10mM magnesium chloride, ImM DTT and 30 ⁇ l of 100 ⁇ g / ml BSA buffer, and 10 units of The restriction enzyme EcoRI (manufactured by Takara Shuzo) and the restriction enzyme SplK (manufactured by Takara Shuzo) were added and reacted at 37 ° C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of an EcoRI-Spll fragment of about 0.39 kb was recovered.
- QIA quick PCR Purification Kit manufactured by Qiagen
- Each plasmid was prepared from 10 transformed Escherichia coli, and the nucleotide sequence was determined according to the method described in Example 1, paragraph 1 (4). As a result, the result was shown in FIG. 14 containing cDNA encoding the desired amino acid sequence.
- the plasmid phKM1732LV0 was obtained.
- the nucleotide sequence of VL (hereinafter referred to as 1732LV0) of the anti-human VEGF receptor Fit-1 human CDR-grafted antibody contained in phKM1732LV0 is shown in SEQ ID NO: 45, and the amino acid sequence is shown in SEQ ID NO: 92.
- VL of the anti-human VEGF receptor Flt-1 human CDR-grafted antibody contained in phKM1750LVO (IV) [hereinafter referred to as 1750 and V0 (IV)] SEQ ID NO: 52 and the amino acid sequence are shown in SEQ ID NO: 93.
- 1750 and V0 (IV) The nucleotide sequence of VL of the anti-human VEGF receptor Flt-1 human CDR-grafted antibody contained in phKM1750LVO (IV) [hereinafter referred to as 1750 and V0 (IV)] SEQ ID NO: 52 and the amino acid sequence are shown in SEQ ID NO: 93.
- VL of anti-human VEGF receptor Fit- 1 human CDR-grafted antibody contained in c PhKM1750 teeth V0 (1) to obtain plasmid phKM1750LV0 (I) is that containing cDNA encoding the amino acid sequence of interest shown in FIG. 33 [hereinafter , 1750LV00)] is shown in SEQ ID NO: 71, and the amino acid sequence is shown in SEQ ID NO: 94.
- Notl a product of Takara Shuzo Co., Ltd.
- 10 units of Notl (a product of Takara Shuzo Co., Ltd.) was further added and allowed to react at 37 ° C. for 1 hour.
- the reaction solution was fractionated by agarose gel electrophoresis, and about 0.5 ⁇ g of an Apal-Notl fragment of about 0.44 kb was recovered.
- the tandem cassette vector for humanized antibody expression obtained in Example 1 2 (1), 0.1 g of the Apat Notl fragment derived from pKANTEX93 and 0.1 g of the Apt Notl fragment derived from the plasmid phKM 1732HV0 obtained above were used in a total amount of 10 g. ⁇ l of sterile water, add DNA ligation Kit Ver.2 (Takara (Manufactured by Shuzo) according to the instructions for use.
- Escherichia coli DH5: strain manufactured by Toyobo Co., Ltd.
- the positions of tyrosine at position 27, alanine at position 40, arginine at position 67, threonine at position 69, isoleucine at position 70, glutamic acid at position 82, glutamic acid at position 82, and palin at position 93 are the amino acid sequences of SEQ ID NO: 45 in VL. Positions 39, leucine 45, leucine 46, aspartic acid 69, and phenylalanine 70 play important roles in binding to human VEGF receptor Fit-1 Was thought.
- VL aspartic acid at position 17 in the amino acid sequence described in SEQ ID NO: 71, arginine at position 18, The positions of proline at position 59, serine at position 59, aspartic acid at position 69, and fujylalanine at position 70 were thought to play important roles in binding to the human VEGF receptor Fit-1.
- Anti-human VEGF receptor Anti-human derived from Fit-1 mouse monoclonal antibody KM1750 The H chain of the VEGF receptor Fit-1 human-type CDR-grafted antibody has three residues among the five amino acid residues shown above, which are thought to play an important role in binding to the human VEGF receptor Flt-1.
- the positions of the groups (glutamic acid at position 82, serine at position 84, tyrosine at position 95) are considered particularly important, so the corresponding residues found at 1750 (glutamine at position 82, arginine at position 84, position 95)
- CDNA encoding the amino acid sequence substituted with phenylalanine was constructed as follows using the PCR method.
- plasmid phKM1750HV0 After treating the plasmid phKM1750HV0 with the restriction enzymes Apal and Mrol, an Apal-Mrol fragment of about 3.04 kb was recovered, the PCR amplified fragment obtained above was ligated, and Escherichia coli DH5 ⁇ was obtained using the obtained recombinant plasmid DNA solution. (Toyobo Co., Ltd.). Each plasmid was prepared from 10 transformed Escherichia coli cells, and the nucleotide sequence was determined according to the method described in Example 1, paragraph 1 (4). As a result, the plasmid containing the cDNA encoding the desired amino acid sequence was obtained. The plasmid phKM1750HV3 shown in (1) was obtained.
- the nucleotide sequence of VH (hereinafter, referred to as 1750HV3) of the anti-human VEGF receptor Fit-1 human CDR-grafted antibody contained in ph M1750HV3 is shown in SEQ ID NO: 78, and the amino acid sequence is shown in SEQ ID NO: 95.
- the light chain of the antibody plays an important role in binding to the human VEGF receptor Flt-1, and 4 residues out of the 6 amino acid residues shown above,
- the positions of aspartic acid at position 17, arginine at position 18, aspartic acid at position 69, and phenylalanine at position 70) are considered to be particularly important in KM175OLV00), so the corresponding residues found in KM1750 (17
- a cDNA encoding the amino acid sequence substituted with glutamic acid at position 18, glutamic acid at position 18, phenylalanine at position 69, and tyrosine at position 70 was constructed using PCR as follows.
- FIG. 46 shows the amino acid sequences of KM1750 mouse L chain, KM1750LV0 (I), KM1750LV (IV), and KM1750LV4.
- coli DH5 ct / pHKM1750LV4 with recombinant plasmid PHKM1750LV4 are FERM BP-6719, FERM BP-6720, FERM BP-6716, FER, respectively.
- BP-6717, FERM BP-6718 have been deposited with the Institute of Biotechnology and Industrial Technology, Institute of Advanced Industrial Science and Technology (1-3 1-3 Higashi, Tsukuba, Ibaraki, Japan) on May 12, 2001.
- G418 manufactured by Gibco
- G418-resistant transformant colonies appeared, culture supernatants were collected from confluent wells, and the activity of the anti-human VEGF receptor Fit-1 human CDR-transferred antibody in the supernatants was measured. The measurement was carried out by the enzyme immunoassay described in section 1 (2) (3).
- Expression vectors pKANTEX 1750HV0LV0 (I), pKANTEX 1750HV0LV0 (IV), pKANTEX 1750HV3LV0 (I), pKANTEX 1750HV3LV0 (IV), pKANTEX-1750HV0LV4, pKANTEX 1750HV3LV4 , KM8550, KM8551, KM8552, and KM8553 are examples of transformants that produce anti-human VEGF receptor Fit-1 human CDR-grafted antibody derived from KM1750, an anti-human VEGF receptor Fit-1 monoclonal antibody.
- the culture supernatant containing the anti-human VEGF receptor Flt-1 human CDR-grafted antibody-producing strains KM8550, KM8551, KM8552, KM8553, M8554, KM8555 prepared as described above was 2.3 L, 2.5, and 1.9, respectively.
- 2.4, 1.1 L and 2 L were passed through a Prosep A column at a flow rate of 70 ml / hour.
- washing is carried out stepwise with 4 ml each of 50 mM citrate buffer at pH 6, pH 5, and pH, followed by 50 mM quench.
- the human CDR-grafted antibody was eluted by passing 7 ml of an acid buffer (pH 3.0) through the column.
- anti-human VEGF receptor Fit-1 human CDR-grafted antibodies KM8550, KM8551, M8552, M8553, KM8554, and K8555 were obtained at l.lmg ⁇ 1.8 mg, 1.6 mg, 1.6 mg, 2.2 mg, 1.3 mg, and 1.6 mg, respectively.
- the purified anti-human VEGF receptor Fit-1 human CDR-grafted antibody ⁇ 8550, ⁇ 8 ⁇ 1, ⁇ 8552, ⁇ 8553, ⁇ 8554, and ⁇ 8555 were analyzed by the SDS-PAGE method described in Example 1, section 2 (3).
- Anti-human VEGF receptor 2 g of the protein amount per lane under reducing and non-reducing conditions Fit- 1 human CDR-grafted antibody KM8550, 855 U KM8552, ⁇ 8553, ⁇ 8554, ⁇ 8 ⁇ ⁇ 2 wherein Example 1 (4)
- the anti-human VEGF receptor Flt-l human chimeric antibody KM2550 and the control human-type CDR-grafted antibody react with gandarioside GM2 and do not react with human VEGF receptor Fit-1 as shown in KM8969 ( JP-A-10-257893) were respectively electrophoresed and stained with Coomassie brilliant blue. The results are shown in FIG. Human CDR-grafted antibody KM8550, KM8551, M8552 N
- M8553, ⁇ 8554, ⁇ 8 ⁇ 5 have a molecular weight of about 150 kDa under non-reducing conditions. Under the reducing conditions, a band of the H chain was observed at about 50 kDa, and a band of the L chain was observed at about 25 kDa. This result indicates that the IgG-type antibody breaks the intermolecular disulfide bond under reducing conditions and breaks down into two heavy and light chains, respectively, and under non-reducing conditions, two heavy and light chains respectively.
- the human CDR-grafted antibodies KM8550, KM8551, KM8552, KM8553, KM8554, and M8555 were shown to be antibody molecules with the correct structure.
- Anti-human VEGF receptor Fit-1 human CDR-grafted antibody KM8550, ⁇ , ⁇ 8552, ⁇ 8553, ⁇ 8554, ⁇ 85 ⁇ and anti-human VEGF receptor Fit-1 human chimeric antibody KM2550 is a human VEGF receptor dependent on antibody concentration Fit- 17N.
- the binding activity of M2550 was almost equivalent. Accordingly, it was revealed that the six human CDR-grafted antibodies of the present invention retain the binding activity of the human chimeric antibody KM2550.
- Figure 43 shows the results.
- Anti-human VEGF receptor Flt-1 human CDR-grafted antibody KM8550, ⁇ 8 ⁇ 1 ⁇ ⁇ 8552, ⁇ 8553, ⁇ 8554, ⁇ 8555 and anti-human VEGF receptor Fit- 1 human chimeric antibody KM2550 showed all comparable reaction specificity, Flt It reacted with 17N, Flt-1 3N, and Flt-1 2N, but did not react with Fit-17N.K2 or KDR7 at all.
- the anti-GM2 human CDR-grafted antibody KM8969 Japanese Patent Laid-Open No. 10-257893
- the six human CDR-grafted antibodies of the present invention retain the binding specificity of the human chimeric antibody KM2550.
- the activity of KM2550 to inhibit the binding between human VEGF and human VEGF receptor Fit-1 was examined according to the method described in Example 1, paragraph 2 (5).
- the antibody concentration to be added was 0.0048 to 15 g / ml (5-fold dilution series).
- the results are shown in FIG.
- KM8555 and anti-human VEGF receptor Fit-1 human chimeric antibody KM2550 inhibited binding of human VEGF to human VEGF receptor Fit-1 in an antibody concentration-dependent manner. Accordingly, it was revealed that the six human CDR-grafted antibodies established in the present invention retain the VEGF-Fk-1 binding inhibitory activity of the human chimeric antibody KM2550.
- a soluble human VEGF receptor Fit-1 fragment (hereinafter referred to as soluble human VEGF receptor Fit-13N) corresponding to positions 1 to 338 (including the signal sequence) from the N-terminal amino acid of human VEGF receptor Fit-1
- C- soluble human VEGF receptor F-13, for which a vector for expression was prepared by the following procedure, is composed of three immunoglobulin-like sites from the N-terminal side of the extracellular region of the soluble human VEGF receptor Fit-1. Is equivalent to
- a soluble human VEGF receptor Fk-1 fragment corresponding to positions 1 to 750 (including the signal sequence) from the N-terminal amino acid of human VEGF receptor Fit-1 (hereinafter referred to as soluble human VEGF receptor Fit-17N)
- a vector for expression was prepared by the following procedure.
- the soluble human VEGF receptor Fit- 17 corresponds to seven immunoglobulin-like sites in the extracellular region of the soluble human VEGF receptor Fit-1.
- DNA 10 ng, and 10 mM deoxynucleotide triphosphate 2.5 units Taq polymerase was added to 100 ⁇ l of a 10 mM MgCl 2 , 0.001% (W / V) gelatin solution containing (deoxynucleotide triphosphates).
- the reaction was pre-treated at 95 ° C for 5 minutes, followed by 30 polymerase 'chain' reactions (PCR) at 95 ° C for 90 seconds, 50 ° C for 90 seconds, and finally 72 ° C for 90 seconds.
- the DNA fragment was recovered repeatedly. This DNA fragment was digested with Hindm (at position 1893 bp in # 3-7 clone) and Notl, and a 610 bp Hindlll-Notl DNA fragment, that is, a 1894-2499 bp fragment and a complete codon in A DNA fragment containing the Notl recognition sequence was recovered. Next, the flt # 3-7 clone was digested with both EcoRl and Hindlll restriction enzymes, and an 1893 bp EcoRI-Hindlll fragment was recovered from the 5 'end.
- Production of protein by insect cells requires the production of a recombinant virus incorporating the gene of interest
- the process of incorporating the cDNA encoding the protein of interest, called transfer vector 1 into a special plasmid
- the virus and the transfer vector are cotransfected into insect cells, and the recombinant virus is obtained by homologous recombination.
- the above process was performed according to the manual according to the manual using the Bakulogo logo starter kit (product number PM-21001K) manufactured by Farmingen.
- the recombinant virus obtained for use in protein expression was propagated by the following procedure. 2 ⁇ 10 7 Sf9 cells were suspended in 10 ml of Sf00-Il medium, placed in a 175 cm 2 flask (manufactured by Grainer Co., Ltd.) and allowed to stand at room temperature for 1 hour to allow the cells to adhere to the flask. After standing, the supernatant was removed, and 1 ml of a fresh culture supernatant containing the TMN-FH Insect Medium and the above recombinant virus was added, followed by culturing at 27 ° C for 3 days. After the culture, the supernatant was centrifuged at 1,500 X g for 10 minutes to remove cells, and a recombinant virus solution used for protein expression was obtained.
- the virus titer of the obtained recombinant virus solution was determined using the Baculo Logo First Starter. —Calculated by the method described in the kit manual (Pharmingen).
- each of the recombinant virus solutions contained about 1 ⁇ 10 7 PFLI / ml of the virus.
- Soluble human VEGF receptors Fit-17N and Fit-13N were obtained as follows. 4 ⁇ 10? High Five cells were suspended in 30 ml of EX-CELL TM 400 medium (manufactured by JRH Bioscience) in a 175 cm 2 flask (manufactured by Grainer), allowed to stand at room temperature for 1 hour, and allowed to adhere to the flask. Add 1 ml of a solution containing the recombinant virus derived from the transfer vectors pVL1393 / Flt 7N and pVL1393 / Flt 3N obtained in (3) at a concentration of about 1-3 ⁇ 10 8 PFU / ml, and infect for 2 hours at room temperature. I let it.
- the culture supernatant was removed and a fresh 30 ml of EX-CELL TM 400 medium was added, followed by culturing at 27 ° C for 3 to 4 days. After completion of the culture, the culture supernatant was collected and centrifuged at 1,500 X g for 10 minutes to obtain a supernatant.
- the column was filled with approximately 60 ml of heparin-sepharose CL-6B gel (Pharmacia Biotech AB) and 0.5 ml of 20 ml of 20 mM Tris-hydrochloric acid (pH 7.5) buffer. The column was washed at a flow rate of / min. After washing, 1000 ml of the culture solution containing the soluble human VEGF receptor Fit-17 and Flt-13 prepared as described above was passed through a heparin-sepharose CL-6B column at a flow rate of 0.5 ml / min.
- the column was filled with approximately 20 ml of heparin-sepharose CL-6B gel (Pharmacia Biotech AB) and 0.5 ml / min using 200 ml of 20 mM Tris-HCl (pH 7.5) buffer. Wash at flow rate. After washing, 500 ml of the culture solution of High Five cells prepared as described above was passed through a heparin-sepharose CL-6B column at a flow rate of 0.5 ml / min.
- Methanol was dispensed into a 96-well Immobilon TM -P Filtration Plate (96-well Immobilon TM -P Filtration Plate; manufactured by Millipore) at 100 ⁇ l / well to hydrophilize the PVDF membrane at the bottom of the plate.
- PBS-diluted 2 ⁇ g / ml soluble human Fit-17N was dispensed at 50 ⁇ l / well, and allowed to stand at 4 ° C. for adsorption. After washing, 100 ⁇ l / well of PBS containing 1% bovine serum albumin (BSA) was added, and the mixture was reacted at room temperature for 1 hour to block the remaining active groups.
- BSA bovine serum albumin
- Human VEGF was obtained as follows. 4 ⁇ 10 7 High Five cells were suspended in 30 ml of EX-CELL TM 400 medium (manufactured by JRH Bioscience) in a 175 cm 2 flask (manufactured by Grina), allowed to stand at room temperature for 1 hour, and allowed to adhere to the flask. 1 ml of a solution containing human VEGF recombinant baculovirus solution obtained by the method described in the literature [Cell Growth & Differentiation, 7, 213 (1996)] at a concentration of about 1 to 3 ⁇ 10 8 PFU / ml, was added at room temperature. Time infected.
- the culture supernatant was removed and a fresh 30 ml of EX-CELL TM 400 medium was added, followed by culturing at 27 ° C for 3 to 4 days. After completion of the culture, the culture supernatant was recovered and centrifuged at 1,500 X g for 10 minutes to obtain a supernatant.
- the column was filled with about 40 ml of heparin-Sepharose C-6B gel (Pharmacia Biotech AB) and 400 ml of 20 mM Tris-HCl (pH 7.5). Washing was performed at a flow rate of 0.5 ml / min using a buffer solution. After washing, human prepared as above
- the protein contained in each fraction was analyzed by SDS polyacrylamide gel electrophoresis, and 120 ml of a fraction containing human VEGF (0.5-1 M NaCl fraction) was collected. After concentration with Centriprep-10 (manufactured by Amicon), 4 ml (protein concentration: 1.2 mg / ml) of human VEGF was obtained as a solution.
- NIH3 Ding 3-Flt- 1 cells IX 10 7 pieces of N 5 Shureimesu BALB (manufactured by Nippon SLC Co., Ltd.) in 3 animals, were administered a total of six times. Blood was collected from the fundus venous plexus or the tail vein, and its serum antibody titer was examined by the enzyme immunoassay shown below. The spleen was extracted 3 days after the last immunization from a mouse or rat showing a sufficient antibody titer. The BALB / c 5-week-old female to which NIH3T3-F-1 cells had been administered had no immunity, and the antibody titer to soluble Fit- 17N did not increase.
- Spleen is shredded in MEM medium (Nissui Pharmaceutical Co., Ltd.), loosened with forceps, and centrifuged
- the 8-azaguanine-resistant mouse myeloma cell line P3-shi'1 was cultured in a normal medium to secure 2 ⁇ 10 7 or more cells at the time of cell fusion and used as a parent strain for cell fusion.
- mice spleen cells or rat spleen cells obtained in 2 and the myeloma cells obtained in 4 were mixed at a ratio of 10: 1, centrifuged (1, 200 rpm, 5 minutes), and the supernatant was discarded. After loosening the precipitated cell group, 37 with stirring.
- 5 clones and 6 clones of anti-human VEGF receptor Fit-1 monoclonal antibodies were obtained, and these were respectively identified as KM1737, K1739, M1740, KM1742, KM1743 and KM1743.
- KM1731, KM1732 Named KM1731, KM1732.
- three clones of KM1732, KM1748, and KM1750 were found to exhibit the inhibitory effect of human VEGF on Fit-1 binding shown in 8 below.
- the three clones of M1730, KM1731 and KM1732 reacted extremely strongly with human VEGF receptor Fk-1 expressing cells in the immunocytostaining method shown in 10 below.
- the antibody class of the monoclonal antibody was determined by an enzyme immunoassay using a subcluster typing kit (Zymet MZymed). The results are shown in Table 4 below. Table 4
- Pristane-treated 8-week-old nude female mice (Balb / c) were injected intraperitoneally with 5-20 ⁇ 10 6 cells of the hybridoma strain obtained in 5 above. After 10 to 21 days, the hybridoma became ascites carcinoma. From accumulated mouse ascites, ascites collected (1 ⁇ 8ml / animal), centrifugal away (3,00 (p m, 5 min) and the force prills acid precipitation after removal of the solids (anti body Ichizu The product was purified according to the manufacturer's manual.
- the specificity of the anti-human VEGF receptor Fit-1 monoclonal antibody obtained in 5 was confirmed using the enzyme immunoassay described in 3.
- Hybridomas were prepared from mice and rats immunized with Flt-17N, Among the monoclonal antibodies (KM1733, M1735, 1736, KM1737, KM1739, KM1740, M1742, KM1743, KM1745, M1746, KM1747) selected using Flt-1 7N, only KM1740 has Fit- 17 and Fit- 13 From the N-terminal amino acid of Flt-1 (including the signal sequence), it was revealed that the peptide recognized the 1-338th epitope. The remaining 10 clones react with Flt-17 but do not react with Fit-13N, and thus recognize the 339-750th epitope from the N-terminal amino acid of Flt-1 (including the signal sequence).
- hybridomas were prepared from mice immunized with Fit-17N, and six monoclonal antibodies selected using Flt-13N (KM1748, KM1749, KM1750, KM1730, KM1731, K1732) All reacted with Flt-1 7N and Fit-13N, indicating that they recognized the epitopes 1-338 from the N-terminal amino acid of Flt-1 (including the signal sequence). became.
- the binding inhibitory activity of the anti-human VEGF receptor Fit-1 monoclonal antibody obtained in step 5 between human VEGF and human VEGF receptor Fit-1 was confirmed according to the following procedure.
- Methanol was dispensed into a 96-well MultiScreen IP plate (96-well MultiScreen-IP Plate; manufactured by Millipore) at 100 ⁇ l / well to hydrophilize the PVDF membrane at the bottom of the plate.
- a soluble human VEGF receptor Flt — 17N diluted to a concentration of 1.6 / zg / ml with PBS was dispensed at 50 ⁇ l / well, and allowed to stand overnight at 4 ° C. for adsorption.
- PBS containing 1% bovine serum albumin (BSA) was added at 50 / il / well, and reacted at room temperature for 1 hour to block the remaining active groups.
- BSA bovine serum albumin
- a purified monoclonal antibody (0.01 to 7 ⁇ 29 ⁇ g / ml) diluted with the culture supernatant of hybridoma or 1% BSA-PBS solution containing 0.5 M NaCl is dispensed at 50 ⁇ l / well. Then, 3 ⁇ g / ml of 12- labeled human VEGF (manufactured by Amersham) was added at 50 ⁇ l / ml, and reacted at room temperature for 1.5 hours.
- FIG. 24 shows the results of examining the activity of the culture supernatant of the hybridoma.
- a monoclonal antibody-producing hybridoma is screened using the same protein as the antigen used for the immunogen. This time, a total of 11 monoclonal antibodies selected with Flt_l7N used as the immunogen did not show any binding inhibitory activity, and the six monoclonal antibodies selected with Fit-13N (KM1748, KM1749, KM1750, KM1730, KM1731, M1732), KM1748, KM1750 and KM1732 showed binding inhibitory activity.
- the use of Flt_l3N for screening of hybridomas resulted in the acquisition of a monoclonal antibody having binding inhibitory activity, which was an unexpected effect.
- FIG. 25 shows the results of examining the binding inhibitory activity using the purified anti-Fit-1 monoclonal antibodies KM1732, KM1748, and KM1750.
- KM1732, KM1748, and KM1750 inhibited the binding of human VEGF to human VEGF receptor Fit-1 in a concentration-dependent manner.
- the concentrations (IC50) of KM1732, KM1748, and KM1750 showing 50% inhibition of binding between human VEGF and human VEGF receptor Flt-1 were 1.1 ⁇ g / ml and 1.3 ⁇ g / mU 2.0 ⁇ g / ml.
- mouse IgGl class anti-sialyl Lewis A monoclonal antibody KM231 [Anticancer
- a 96-well multiscreen-HV plate (96-well ultiScreen-HV Plate; manufactured by Millipore) was added with 100 ⁇ l / well of PBS containing 1% bovine serum albumin (BSA), and allowed to react at room temperature for 1 hour.
- BSA bovine serum albumin
- NIH3T3-Fit-1 cells suspended in 1% BSA-PBS containing 0.05% NaN 3 after blocking the active groups were added at 5 ⁇ 10 4 cells / well.
- the purified monoclonal antibody (0.01-7.29 mu g / ml) was dispensed in 50 mu 1 / Ueru, further, 3 ng / ml of 125 1-labeled human VEGF (manufactured by Amersham) 50 ⁇ ⁇ / ⁇ ⁇ was added and reacted on ice for 2 hours.
- After washing with PBS dry the wells at 50 ° C and use MicroScint-0 (Packard The Ltd.) 30 mu 1 / Ueru addition, using a Top Count (manufactured by Packard) to measure the radioactivity of 125 1-labeled human VEGF bound to each Ueru.
- FIG. 26 shows the results of examining the binding inhibitory activity using the purified anti-Fit-1 monoclonal antibodies KM1732, KM1748, and KM1750.
- M1732, KM1748 and KM1750 inhibited the binding of human VEGF to NIH3T3-Fit-1 cells in a concentration-dependent manner.
- the concentrations (ICS0) of KM1732, M1748, and KM1750 that show 50% inhibition of binding between human VEGF and NIH3T3-Flt-1 cells were ⁇ . ⁇ ⁇ g / mU 0.037 ⁇ g / ml and 0.041 ⁇ g / ml .
- the mouse IgGl class anti-sialyl Lewis A monoclonal antibody KM231 used as a control did not show any inhibitory activity.
- the specificity of the anti-human VEGF receptor Fit-1 monoclonal antibody obtained in step 5 was confirmed by using the immunocell staining according to the following procedure.
- NIH3T3-Fit-1 Human VEGF receptor Fit-1 expressing NIH3T3 cells
- control N1H3T3 cells NIH3T3-Neo [Oncogene, 10, 135 (1995)] 5 x 10 6 cells in a round bottom 96 ⁇ L plate
- the suspension was dispensed in 100 ⁇ l of a buffer for staining immunological cells (PBS containing 1% BSA, 0.02% EDTA and 0.05% sodium azide) and dispensed.
- PBS containing 1% BSA, 0.02% EDTA and 0.05% sodium azide
- an immunocell staining buffer containing FITC-labeled anti-mouse immunoglobulin antibody or FITC-labeled anti-rat immunoglobulin antibody (manufactured by Wako Pure Chemical Industries, Ltd.) at a concentration of 1 ⁇ g / ml is used. ⁇ 1 was added and the reaction was carried out at 4 for 30 minutes. After the reaction, the same washing operation as described above was performed three times, and then analyzed using a flow cytometer (manufactured by Coulter).
- the results are shown in FIG.
- the anti-human VEGF receptor Flt_l monoclonal antibodies KM1730, KM1731, and KM1732 did not react with control cells but specifically and remarkably reacted with Flt- ⁇ expressing cells (A).
- purified human anti-human VEGF receptor Fit-1 monoclonal antibody ⁇ 1748 (10 ⁇ g / ml) and hybridoma culture supernatant KM1748 do not react with control cells but are specific to Fit-1 expressing cells.
- the monoclonal antibodies KM1730, M1731, 1732, KM 1748 and KM1750 are It has been found that it specifically recognizes human VEGF receptor Fit-1.
- KM1735, M1736, KM1742, KM1743 and KM1745 reacted with cells expressing human VEGF receptor Fit-1, but were extremely weaker than KM1730, M1731, KM1732, KM1748 and KM1750.
- Cell membrane components were prepared from NIH3T3-Fit-1 cells and control NIH3T3 cells (N1H3T3-Neo) according to the method described in the literature [Cancer Research, 46, 4438 (1986)], and electrophoresed by SDS-PAGE.
- the SDS-PAGE was performed according to the method described in the literature [Anticancer Research, 12 ⁇ 1121 (1992)].
- the gel used was a 5-20% gradient gel (manufactured by Atto Co., Ltd.). 15 ⁇ g of the cell membrane component was electrophoresed as the protein mass per cell.
- the electrophoresed protein was transferred to a PVDF membrane according to the method described in the literature [Anticancer Research, 12, 1121 (1 "2).
- the PVDF membrane was reacted with PBS containing 1% BSA at room temperature for 30 minutes.
- a blocking operation was performed, and the culture supernatant of the anti-human VEGF receptor Fit-1 monoclonal antibody KM1737 was reacted at 4 ° C. for 1 ° C.
- the plate was washed with PBS containing 0.05% Tween and peroxidase-labeled goat antibody.
- the mouse lgG [5,000-fold dilution: Chemicon] was reacted for 2 hours at room temperature, washed with PBS containing 0.05% Tween, and washed with ECL TM Western Blotting Deg. detectionreagents (manufactured by Amersham) was used to detect the band bound to the anti-human VEGF receptor Fit-1 monoclonal antibody KM1737.
- Figure 28 shows the results. It was revealed that the anti-human VEGF receptor Fit-1 monoclonal antibody KM1737 can specifically detect the human VEGF receptor Fit-1 having a molecular weight of 180 kilodaltons expressed in NIH3T3-Fit-1 cells.
- BSA bovine serum albumin
- the cell migration test was performed according to the method of Sato et al. [J. Cell Biology, 107, 1199 (1988)]. HUVECs cultured to confluence in a 3.5 cm dish were wounded with a razor blade and washed with PBS. Add 1.5 ml of M-199 medium containing 5% FCS, add VEGF (final concentration lOng / ml) and anti-VEGF receptor Fit-1 monoclonal antibody KM1750 or KM1732 obtained in 5 (final concentration 0, 1, 10 ⁇ l). g / ml) and cultured for 24 hours. After the culture, the number of cells migrated from the damaged position was measured.
- FIG. 47 shows the results of comparing the activity of the anti-VEGF receptor Flt_l monoclonal antibodies KM1750 and KM1732 to inhibit the migration of vascular endothelial cells.
- a recombinant antibody that specifically binds to a human VEGF receptor Flt-1 which is considered to be specifically expressed on neonatal human vascular endothelial cells. Further, the present invention provides a recombinant antibody having a neutralizing activity against human VEGF receptor Fit-1.
- the recombinant antibody of the present invention is useful for diagnosis, treatment, etc. of angiogenesis-related diseases such as cancer and diabetic retinopathy, and particularly, its effect in humans is lower in immunogenicity than mouse monoclonal antibody. Is expected to last for a long time. Sequence listing free text
- SEQ ID NO: 28 Description of artificial sequence: Synthetic DNA
- SEQ ID NO: 31 Description of artificial sequence: Synthetic DNA SEQ ID No. 32—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 33—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 34—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 35—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 36—Artificial Sequence Description: Synthetic DNA SEQ ID No. 37—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 38—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 39—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 40—Description of Artificial Sequence: Synthetic DNA Sequence No. 41 Description of Artificial Sequence: Synthetic DNA SEQ ID No.
- SEQ ID NO: 65 Description of Artificial Sequence: Synthetic DNA
- SEQ ID NO: 70 Description of Artificial Sequence: Synthetic DNA
- SEQ ID NO: 86 Description of artificial sequence: variable region of humanized antibody heavy chain
- SEQ ID NO: 87 Description of artificial sequence: variable region of humanized antibody light chain
- SEQ ID NO: 88 Description of artificial sequence: variable region of humanized antibody heavy chain
- SEQ ID NO: 89 Description of artificial sequence: variable region of humanized antibody light chain
- SEQ ID NO: 90 Description of artificial sequence: variable region of humanized antibody heavy chain
- SEQ ID NO: 92 Description of artificial sequence: variable region of humanized antibody light chain
- SEQ ID NO: 93 Description of artificial sequence: variable region of humanized antibody light chain
- SEQ ID NO: 94 Description of artificial sequence: variable region of humanized antibody light chain
- SEQ ID NO: 95 Description of artificial sequence: variable region of humanized antibody heavy chain
- SEQ ID NO: 96 Description of artificial sequence: variable region of humanized antibody light chain
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99921206T ATE428732T1 (de) | 1998-05-20 | 1999-05-20 | Gen rekombinante antikörper |
CA002328986A CA2328986A1 (en) | 1998-05-20 | 1999-05-20 | Gene recombinant antibodies |
AU38503/99A AU767731B2 (en) | 1998-05-20 | 1999-05-20 | Gene recombinant antibodies |
DE69940733T DE69940733D1 (de) | 1998-05-20 | 1999-05-20 | Gen rekombinante antikörper |
EP99921206A EP1086956B1 (en) | 1998-05-20 | 1999-05-20 | Gene recombinant antibodies |
US09/453,718 US6986890B1 (en) | 1996-11-21 | 1999-12-03 | Anti-human VEGF receptor Flt-1 monoclonal antibody |
US10/160,232 US7052693B2 (en) | 1996-11-21 | 2002-06-04 | Anti-human VEGF receptor FLT-1 monoclonal antibody |
AU2004200700A AU2004200700B2 (en) | 1998-05-20 | 2004-02-20 | Gene Recombinant Antibody |
US11/250,411 US7615214B2 (en) | 1996-11-21 | 2005-10-17 | Anti-human VEGF receptor Flt-1 monoclonal antibody |
US11/277,121 US7615215B2 (en) | 1996-11-21 | 2006-03-21 | Anti-human VEGF receptor Flt-1 monoclonal antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13900098 | 1998-05-20 | ||
JP10/139000 | 1998-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999060025A1 true WO1999060025A1 (fr) | 1999-11-25 |
Family
ID=15235143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/002661 WO1999060025A1 (fr) | 1996-11-21 | 1999-05-20 | Anticorps recombines de gene |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1086956B1 (ja) |
AT (1) | ATE428732T1 (ja) |
AU (1) | AU767731B2 (ja) |
CA (1) | CA2328986A1 (ja) |
DE (1) | DE69940733D1 (ja) |
ES (1) | ES2325642T3 (ja) |
WO (1) | WO1999060025A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1151002A1 (en) * | 1999-01-29 | 2001-11-07 | Imclone Systems, Inc. | Antibodies specific to kdr and uses thereof |
WO2005035581A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ヒトVEGF受容体Flt-1に特異的に結合する抗体組成物 |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
US8143025B2 (en) | 2004-11-18 | 2012-03-27 | Imclone Llc | Antibodies against vascular endothelial growth factor receptor-1 |
JP2013116120A (ja) * | 2005-08-26 | 2013-06-13 | Roche Glycart Ag | 改変された細胞シグナル活性有する改変抗原結合分子 |
JP5651893B2 (ja) * | 2004-06-07 | 2015-01-14 | 協和発酵キリン株式会社 | 抗perp抗体 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057067A1 (en) | 2000-02-04 | 2001-08-09 | Supratek Pharma Inc. | Ligand for vascular endothelial growth factor receptor |
GB0323609D0 (en) * | 2003-10-09 | 2003-11-12 | Univ Belfast | A peptide,and use of the peptide to assay for sflt-1 protein |
KR100998569B1 (ko) * | 2008-03-31 | 2010-12-07 | 한국원자력연구원 | 암 또는 전이암 진단 및 치료용 방사면역접합체,및 이를이용한 암 또는 전이암 억제제 개발 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05304989A (ja) * | 1991-09-18 | 1993-11-19 | Kyowa Hakko Kogyo Co Ltd | ヒト型キメラ抗体の製造法 |
JPH06205694A (ja) * | 1992-09-07 | 1994-07-26 | Kyowa Hakko Kogyo Co Ltd | ヒト化抗体 |
WO1995021868A1 (en) * | 1994-02-10 | 1995-08-17 | Imclone Systems Incorporated | Monoclonal antibodies specific to vegf receptors and uses thereof |
WO1998022616A1 (fr) * | 1996-11-21 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2233974T3 (es) * | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
-
1999
- 1999-05-20 EP EP99921206A patent/EP1086956B1/en not_active Expired - Lifetime
- 1999-05-20 DE DE69940733T patent/DE69940733D1/de not_active Expired - Lifetime
- 1999-05-20 AU AU38503/99A patent/AU767731B2/en not_active Ceased
- 1999-05-20 AT AT99921206T patent/ATE428732T1/de not_active IP Right Cessation
- 1999-05-20 ES ES99921206T patent/ES2325642T3/es not_active Expired - Lifetime
- 1999-05-20 CA CA002328986A patent/CA2328986A1/en not_active Abandoned
- 1999-05-20 WO PCT/JP1999/002661 patent/WO1999060025A1/ja active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05304989A (ja) * | 1991-09-18 | 1993-11-19 | Kyowa Hakko Kogyo Co Ltd | ヒト型キメラ抗体の製造法 |
JPH06205694A (ja) * | 1992-09-07 | 1994-07-26 | Kyowa Hakko Kogyo Co Ltd | ヒト化抗体 |
WO1995021868A1 (en) * | 1994-02-10 | 1995-08-17 | Imclone Systems Incorporated | Monoclonal antibodies specific to vegf receptors and uses thereof |
WO1998022616A1 (fr) * | 1996-11-21 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain |
Non-Patent Citations (4)
Title |
---|
BIRD R.E. ET AL: "Single-chain antigen-binding proteins", SCIENCE, vol. 242, no. 4877, 1988, pages 423 - 426 * |
MITOLA S. ET AL: "Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor (Receptor-1)", BLOOD, vol. 90, no. 4, 1997, pages 1365 - 1372, XP002937441 * |
SHIBUYA M. ET AL: "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene(flt) closely related to the fms family", ONCOGENE, vol. 5, no. 4, 1990, pages 519 - 524 * |
WEBBER K.O. ET AL: "Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog", MOL. IMMUNOL., vol. 32, no. 4, 1995, pages 249 - 258 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1151002A1 (en) * | 1999-01-29 | 2001-11-07 | Imclone Systems, Inc. | Antibodies specific to kdr and uses thereof |
EP1151002A4 (en) * | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | KDR-SPECIFIC ANTIBODIES AND USES THEREOF |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
WO2005035581A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ヒトVEGF受容体Flt-1に特異的に結合する抗体組成物 |
JPWO2005035581A1 (ja) * | 2003-10-09 | 2007-11-22 | 協和醗酵工業株式会社 | ヒトVEGF受容体Flt−1に特異的に結合する抗体組成物 |
JP5651893B2 (ja) * | 2004-06-07 | 2015-01-14 | 協和発酵キリン株式会社 | 抗perp抗体 |
US8143025B2 (en) | 2004-11-18 | 2012-03-27 | Imclone Llc | Antibodies against vascular endothelial growth factor receptor-1 |
JP2013116120A (ja) * | 2005-08-26 | 2013-06-13 | Roche Glycart Ag | 改変された細胞シグナル活性有する改変抗原結合分子 |
Also Published As
Publication number | Publication date |
---|---|
AU3850399A (en) | 1999-12-06 |
EP1086956A4 (en) | 2002-08-21 |
CA2328986A1 (en) | 1999-11-25 |
AU767731B2 (en) | 2003-11-20 |
ES2325642T3 (es) | 2009-09-10 |
EP1086956A1 (en) | 2001-03-28 |
ATE428732T1 (de) | 2009-05-15 |
EP1086956B1 (en) | 2009-04-15 |
DE69940733D1 (de) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7615214B2 (en) | Anti-human VEGF receptor Flt-1 monoclonal antibody | |
KR100259828B1 (ko) | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 | |
KR101773216B1 (ko) | 항 cd27 항체 | |
JP5425775B2 (ja) | 抗cd27抗体 | |
EP0882799B1 (en) | Anti-human vegf receptor flt-1 monoclonal antibody | |
WO1999059636A1 (fr) | Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf) | |
JPWO2008114733A1 (ja) | 抗Claudin−4抗体 | |
WO2000035956A1 (fr) | Anticorps monoclonal anti-vegf humain | |
CN107849139B (zh) | 与人crth2特异性结合的抗体 | |
WO1999040118A1 (fr) | Anticorps diriges contre le recepteur kdr humain du vegf | |
KR20190017740A (ko) | 플렉틴-1 결합 항체 및 그의 용도 | |
WO1999060025A1 (fr) | Anticorps recombines de gene | |
US20030175271A1 (en) | VEGF activity inhibitor | |
JP2001046066A (ja) | 新規な相補性決定領域を有するヒトvegf受容体kdrに対する抗体 | |
CN110959014A (zh) | 抗人ccr1单克隆抗体 | |
JP3679406B2 (ja) | 遺伝子組換え抗体 | |
KR20230132450A (ko) | 항trpv6 단일 클론 항체 및 그 응용 | |
EP1199565B1 (en) | Diagnostics and remedies for diseases with participation of macrocytes/macrophages | |
US8093362B2 (en) | Anti-PERP recombinant antibody | |
AU2004200700B2 (en) | Gene Recombinant Antibody | |
EP1160572A1 (en) | Diagnostics and remedies for leukemia | |
WO1999048926A1 (en) | ANTIBODY AGAINST HUMAN α1,3-FUCOSE TRANSFERASE Fuc-TVII |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ HU ID IL IN JP KR MX NO NZ PL RO SG SI SK UA VN ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2328986 Country of ref document: CA Kind code of ref document: A Ref document number: 2328986 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999921206 Country of ref document: EP Ref document number: 38503/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999921206 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 38503/99 Country of ref document: AU |